Morphea: From a Rash to Atrophy

Article Type
Changed
Display Headline
Morphea: From a Rash to Atrophy

Article PDF
Author and Disclosure Information

Aaron C. Garza, MD; and Suresh Kumar, MD

Issue
Federal Practitioner - 30(10)
Publications
Page Number
22-24
Legacy Keywords
morphea, localized scleroderma, atrophy, inflammation, sclerosis, Aaron C. Garza, Suresh Kumar
Sections
Author and Disclosure Information

Aaron C. Garza, MD; and Suresh Kumar, MD

Author and Disclosure Information

Aaron C. Garza, MD; and Suresh Kumar, MD

Article PDF
Article PDF

Issue
Federal Practitioner - 30(10)
Issue
Federal Practitioner - 30(10)
Page Number
22-24
Page Number
22-24
Publications
Publications
Article Type
Display Headline
Morphea: From a Rash to Atrophy
Display Headline
Morphea: From a Rash to Atrophy
Legacy Keywords
morphea, localized scleroderma, atrophy, inflammation, sclerosis, Aaron C. Garza, Suresh Kumar
Legacy Keywords
morphea, localized scleroderma, atrophy, inflammation, sclerosis, Aaron C. Garza, Suresh Kumar
Sections
Article Source

PURLs Copyright

Inside the Article

Article PDF Media

Primary Knee Arthrodesis for Severe Crystalline Arthropathy

Article Type
Changed
Display Headline
Primary Knee Arthrodesis for Severe Crystalline Arthropathy

Article PDF
Author and Disclosure Information

Bryan G. Vopat, MD, Scott A. Ritterman, MD, Stephen Kayiaros, MD, and Lee E. Rubin, MD

Issue
The American Journal of Orthopedics - 42(10)
Publications
Topics
Page Number
E91-E93
Legacy Keywords
ajo, the american journal of orthopedics, knee arthrodesis, crystalline arthropathy, arthritis, joint, knee, gout
Sections
Author and Disclosure Information

Bryan G. Vopat, MD, Scott A. Ritterman, MD, Stephen Kayiaros, MD, and Lee E. Rubin, MD

Author and Disclosure Information

Bryan G. Vopat, MD, Scott A. Ritterman, MD, Stephen Kayiaros, MD, and Lee E. Rubin, MD

Article PDF
Article PDF

Issue
The American Journal of Orthopedics - 42(10)
Issue
The American Journal of Orthopedics - 42(10)
Page Number
E91-E93
Page Number
E91-E93
Publications
Publications
Topics
Article Type
Display Headline
Primary Knee Arthrodesis for Severe Crystalline Arthropathy
Display Headline
Primary Knee Arthrodesis for Severe Crystalline Arthropathy
Legacy Keywords
ajo, the american journal of orthopedics, knee arthrodesis, crystalline arthropathy, arthritis, joint, knee, gout
Legacy Keywords
ajo, the american journal of orthopedics, knee arthrodesis, crystalline arthropathy, arthritis, joint, knee, gout
Sections
Article Source

PURLs Copyright

Inside the Article

Article PDF Media

Isolated Vastus Lateralis Tendon Avulsion

Article Type
Changed
Display Headline
Isolated Vastus Lateralis Tendon Avulsion

Article PDF
Author and Disclosure Information

Jonathan M. Frank, MD, Matthew D. Riedel, BA, Frank M. McCormick, MD, and Shane J. Nho, MD

Issue
The American Journal of Orthopedics - 42(10)
Publications
Topics
Page Number
464-465
Legacy Keywords
ajo, the american journal of orthopedics, tendon, knee, isolated vastus lateralis
Sections
Author and Disclosure Information

Jonathan M. Frank, MD, Matthew D. Riedel, BA, Frank M. McCormick, MD, and Shane J. Nho, MD

Author and Disclosure Information

Jonathan M. Frank, MD, Matthew D. Riedel, BA, Frank M. McCormick, MD, and Shane J. Nho, MD

Article PDF
Article PDF

Issue
The American Journal of Orthopedics - 42(10)
Issue
The American Journal of Orthopedics - 42(10)
Page Number
464-465
Page Number
464-465
Publications
Publications
Topics
Article Type
Display Headline
Isolated Vastus Lateralis Tendon Avulsion
Display Headline
Isolated Vastus Lateralis Tendon Avulsion
Legacy Keywords
ajo, the american journal of orthopedics, tendon, knee, isolated vastus lateralis
Legacy Keywords
ajo, the american journal of orthopedics, tendon, knee, isolated vastus lateralis
Sections
Article Source

PURLs Copyright

Inside the Article

Article PDF Media

Diagnosis at a Glance

Article Type
Changed
Display Headline
Diagnosis at a Glance

Case 1Case submitted by Ms Patel and Dr Schleicher.    A 54-year-old woman presents to the ED for evaluation of an asymptomatic lesion on her right forearm, which she states developed several weeks before presentation. She has a history of hypertension and thyroid disease, for which she takes several medications (none recently commenced). She admits to ample past sun exposure from living in Florida for 30 years, but denies a history of skin cancer. Examination reveals a well-demarcated, slightly elevated, annular dusky erythematous plaque with scale. No similar lesions are noted elsewhere. A dermatology consult is requested for biopsy. What is your diagnosis?

Case 2Case submitted by Ms Remaly and Dr Schleicher.    A 32-year-old woman without a significant medical history presents with a facial eruption of 3 days’ duration. She states that the rash began with swelling and redness on her left eye, at which time she visited a local ED, was diagnosed with cellulitis, and prescribed cephalosporin and a topical antibiotic. The dermatitis, however, continued to intensify to the point where she is now unable to open her eye due to the edema. Patient denies any other discomfort. On physical examination, she is noted to have a well-demarcated dermatitis manifesting clinically as erythema and vesicles. Preauricular and cervical lymph nodes are nonpalpable. What is your diagnosis?

Ms Patel is a second year medical student at the Commonwealth Medical College in Scranton, Pennsylvania. Ms Remaley is a physician assistant at Reading Dermatology Associates in Reading, Pennsylvania. Dr Schleicher, editor of “Diagnosis at a Glance,” is director of the DermDOX Center in Hazleton, Pennsylvania, a clinical instructor of dermatology at King’s College in Wilkes-Barre, Pennsylvania, an associate professor of medicine at the Commonwealth Medical College in Scranton, Pennsylvania, and an adjunct assistant professor of dermatology at the University of Pennsylvania in Philadelphia. He is also a member of the EMERGENCY MEDICINE editorial board.

Answer

Case 1

The histopathology of the punch biopsy revealed a lichenoid actinic keratosis (LAK). The term lichenoid refers to a mixed cell inflammatory infiltrate that involves the dermo-epidermal junction. Actinic or solar keratoses are induced in fair-skinned individuals by cumulative exposure to sunlight and are considered premalignant lesions. The LAK variant occurs as a solitary lesion on the extensor surfaces of the arms and, less commonly, on the face. Not clinically distinctive, LAK may resemble lichen planus or a fixed drug eruption. Subjective symptoms are minimal or absent. As a small percentage of actinic keratoses may evolve into squamous cell carcinomas, eradication is generally recommended. Current surgical and topical treatment options include cryosurgery, curettage (with or without electrosurgery), photodynamic surgery, fluorouracil, diclofenac 3%, imiquimod 5%, and ingenol mebutate.

Case 2

The patient’s symptoms are characteristic of reactivation of varicella-zoster virus (VZV) within dorsal root ganglia, resulting in herpes zoster. Since the eye is affected in up to 50% of cases, involvement of the ophthalmic branches of the trigeminal nerve is a medical emergency requiring aggressive treatment.1 Complications of herpes zoster ophthalmicus (HZO) include iritis, glaucoma, corneal tissue ulcerations, and loss of vision. Sequelae may also include scarring and postherpetic neuralgia. HZO warrants systemic antiviral therapy, which is best commenced within
72 hours of onset.2

References

1. Catron T, Hern HG. Herpes zoster ophthalmicus. West J Emerg Med. 2008;9(3):174-176.

2. Shaikh S, Ta CN. Evaluation and management of herpes zoster ophthalmicus. Am Fam Physician. 2002;66(9):1723-1730.

Author and Disclosure Information

Issue
Emergency Medicine - 45(10)
Publications
Topics
Page Number
33-34
Legacy Keywords
Diagnosis at a Glance
Sections
Author and Disclosure Information

Author and Disclosure Information

Case 1Case submitted by Ms Patel and Dr Schleicher.    A 54-year-old woman presents to the ED for evaluation of an asymptomatic lesion on her right forearm, which she states developed several weeks before presentation. She has a history of hypertension and thyroid disease, for which she takes several medications (none recently commenced). She admits to ample past sun exposure from living in Florida for 30 years, but denies a history of skin cancer. Examination reveals a well-demarcated, slightly elevated, annular dusky erythematous plaque with scale. No similar lesions are noted elsewhere. A dermatology consult is requested for biopsy. What is your diagnosis?

Case 2Case submitted by Ms Remaly and Dr Schleicher.    A 32-year-old woman without a significant medical history presents with a facial eruption of 3 days’ duration. She states that the rash began with swelling and redness on her left eye, at which time she visited a local ED, was diagnosed with cellulitis, and prescribed cephalosporin and a topical antibiotic. The dermatitis, however, continued to intensify to the point where she is now unable to open her eye due to the edema. Patient denies any other discomfort. On physical examination, she is noted to have a well-demarcated dermatitis manifesting clinically as erythema and vesicles. Preauricular and cervical lymph nodes are nonpalpable. What is your diagnosis?

Ms Patel is a second year medical student at the Commonwealth Medical College in Scranton, Pennsylvania. Ms Remaley is a physician assistant at Reading Dermatology Associates in Reading, Pennsylvania. Dr Schleicher, editor of “Diagnosis at a Glance,” is director of the DermDOX Center in Hazleton, Pennsylvania, a clinical instructor of dermatology at King’s College in Wilkes-Barre, Pennsylvania, an associate professor of medicine at the Commonwealth Medical College in Scranton, Pennsylvania, and an adjunct assistant professor of dermatology at the University of Pennsylvania in Philadelphia. He is also a member of the EMERGENCY MEDICINE editorial board.

Answer

Case 1

The histopathology of the punch biopsy revealed a lichenoid actinic keratosis (LAK). The term lichenoid refers to a mixed cell inflammatory infiltrate that involves the dermo-epidermal junction. Actinic or solar keratoses are induced in fair-skinned individuals by cumulative exposure to sunlight and are considered premalignant lesions. The LAK variant occurs as a solitary lesion on the extensor surfaces of the arms and, less commonly, on the face. Not clinically distinctive, LAK may resemble lichen planus or a fixed drug eruption. Subjective symptoms are minimal or absent. As a small percentage of actinic keratoses may evolve into squamous cell carcinomas, eradication is generally recommended. Current surgical and topical treatment options include cryosurgery, curettage (with or without electrosurgery), photodynamic surgery, fluorouracil, diclofenac 3%, imiquimod 5%, and ingenol mebutate.

Case 2

The patient’s symptoms are characteristic of reactivation of varicella-zoster virus (VZV) within dorsal root ganglia, resulting in herpes zoster. Since the eye is affected in up to 50% of cases, involvement of the ophthalmic branches of the trigeminal nerve is a medical emergency requiring aggressive treatment.1 Complications of herpes zoster ophthalmicus (HZO) include iritis, glaucoma, corneal tissue ulcerations, and loss of vision. Sequelae may also include scarring and postherpetic neuralgia. HZO warrants systemic antiviral therapy, which is best commenced within
72 hours of onset.2

References

1. Catron T, Hern HG. Herpes zoster ophthalmicus. West J Emerg Med. 2008;9(3):174-176.

2. Shaikh S, Ta CN. Evaluation and management of herpes zoster ophthalmicus. Am Fam Physician. 2002;66(9):1723-1730.

Case 1Case submitted by Ms Patel and Dr Schleicher.    A 54-year-old woman presents to the ED for evaluation of an asymptomatic lesion on her right forearm, which she states developed several weeks before presentation. She has a history of hypertension and thyroid disease, for which she takes several medications (none recently commenced). She admits to ample past sun exposure from living in Florida for 30 years, but denies a history of skin cancer. Examination reveals a well-demarcated, slightly elevated, annular dusky erythematous plaque with scale. No similar lesions are noted elsewhere. A dermatology consult is requested for biopsy. What is your diagnosis?

Case 2Case submitted by Ms Remaly and Dr Schleicher.    A 32-year-old woman without a significant medical history presents with a facial eruption of 3 days’ duration. She states that the rash began with swelling and redness on her left eye, at which time she visited a local ED, was diagnosed with cellulitis, and prescribed cephalosporin and a topical antibiotic. The dermatitis, however, continued to intensify to the point where she is now unable to open her eye due to the edema. Patient denies any other discomfort. On physical examination, she is noted to have a well-demarcated dermatitis manifesting clinically as erythema and vesicles. Preauricular and cervical lymph nodes are nonpalpable. What is your diagnosis?

Ms Patel is a second year medical student at the Commonwealth Medical College in Scranton, Pennsylvania. Ms Remaley is a physician assistant at Reading Dermatology Associates in Reading, Pennsylvania. Dr Schleicher, editor of “Diagnosis at a Glance,” is director of the DermDOX Center in Hazleton, Pennsylvania, a clinical instructor of dermatology at King’s College in Wilkes-Barre, Pennsylvania, an associate professor of medicine at the Commonwealth Medical College in Scranton, Pennsylvania, and an adjunct assistant professor of dermatology at the University of Pennsylvania in Philadelphia. He is also a member of the EMERGENCY MEDICINE editorial board.

Answer

Case 1

The histopathology of the punch biopsy revealed a lichenoid actinic keratosis (LAK). The term lichenoid refers to a mixed cell inflammatory infiltrate that involves the dermo-epidermal junction. Actinic or solar keratoses are induced in fair-skinned individuals by cumulative exposure to sunlight and are considered premalignant lesions. The LAK variant occurs as a solitary lesion on the extensor surfaces of the arms and, less commonly, on the face. Not clinically distinctive, LAK may resemble lichen planus or a fixed drug eruption. Subjective symptoms are minimal or absent. As a small percentage of actinic keratoses may evolve into squamous cell carcinomas, eradication is generally recommended. Current surgical and topical treatment options include cryosurgery, curettage (with or without electrosurgery), photodynamic surgery, fluorouracil, diclofenac 3%, imiquimod 5%, and ingenol mebutate.

Case 2

The patient’s symptoms are characteristic of reactivation of varicella-zoster virus (VZV) within dorsal root ganglia, resulting in herpes zoster. Since the eye is affected in up to 50% of cases, involvement of the ophthalmic branches of the trigeminal nerve is a medical emergency requiring aggressive treatment.1 Complications of herpes zoster ophthalmicus (HZO) include iritis, glaucoma, corneal tissue ulcerations, and loss of vision. Sequelae may also include scarring and postherpetic neuralgia. HZO warrants systemic antiviral therapy, which is best commenced within
72 hours of onset.2

References

1. Catron T, Hern HG. Herpes zoster ophthalmicus. West J Emerg Med. 2008;9(3):174-176.

2. Shaikh S, Ta CN. Evaluation and management of herpes zoster ophthalmicus. Am Fam Physician. 2002;66(9):1723-1730.

Issue
Emergency Medicine - 45(10)
Issue
Emergency Medicine - 45(10)
Page Number
33-34
Page Number
33-34
Publications
Publications
Topics
Article Type
Display Headline
Diagnosis at a Glance
Display Headline
Diagnosis at a Glance
Legacy Keywords
Diagnosis at a Glance
Legacy Keywords
Diagnosis at a Glance
Sections
Article Source

PURLs Copyright

Inside the Article

Missed Rotator Cuff Tears in Polytraumatized Patients

Article Type
Changed
Display Headline
Missed Rotator Cuff Tears in Polytraumatized Patients

Article PDF
Author and Disclosure Information

Charles S. Grimshaw, MD, Lisa K. Cannada, MD, Adnan Cutuk, MD, and Scott G. Kaar, MD

Issue
The American Journal of Orthopedics - 42(10)
Publications
Topics
Page Number
466-469
Legacy Keywords
ajo, the american journal of orthopedics, rotator cuff tear, polytraumatized patient, shoulder
Sections
Author and Disclosure Information

Charles S. Grimshaw, MD, Lisa K. Cannada, MD, Adnan Cutuk, MD, and Scott G. Kaar, MD

Author and Disclosure Information

Charles S. Grimshaw, MD, Lisa K. Cannada, MD, Adnan Cutuk, MD, and Scott G. Kaar, MD

Article PDF
Article PDF

Issue
The American Journal of Orthopedics - 42(10)
Issue
The American Journal of Orthopedics - 42(10)
Page Number
466-469
Page Number
466-469
Publications
Publications
Topics
Article Type
Display Headline
Missed Rotator Cuff Tears in Polytraumatized Patients
Display Headline
Missed Rotator Cuff Tears in Polytraumatized Patients
Legacy Keywords
ajo, the american journal of orthopedics, rotator cuff tear, polytraumatized patient, shoulder
Legacy Keywords
ajo, the american journal of orthopedics, rotator cuff tear, polytraumatized patient, shoulder
Sections
Article Source

PURLs Copyright

Inside the Article

Article PDF Media

A nondrug approach to dementia

Article Type
Changed
Display Headline
A nondrug approach to dementia

Practice recommendations

› Attempt nonpharmacologic treatment for dementia behavioral problems before moving on to medications, which are of questionable efficacy for symptoms other than aggression and psychosis. A
› Obtain informed consent from patients and/or their caregivers if you plan to use antipsychotic medications because their use increases morbidity and mortality in the elderly. A

Strength of recommendation (SOR)

A Good-quality patient-oriented evidence
B Inconsistent or limited-quality patient-oriented evidence
C Consensus, usual practice, opinion, disease-oriented evidence, case series

CASE Ms. M, 86 years old, lives with her daughter, son-in-law, and granddaughter. For several years she has been forgetful, but she has never had a formal work-up for dementia. Her daughter finally brings her to their primary care physician because she was refusing to take showers, was increasingly irritable, and had tried to hit her daughter’s husband.

In the office, however, Ms. M is calm and pleasant. The family says that most nights Ms. M gets up and wanders around the house. She denies feeling depressed or anxious, but her Folstein Mini-Mental State Exam score is 22/30, indicating moderate dementia. (For more on assessment, see “Tools for assessing patients with dementia—and their caregivers” on page 552.)

The physician offers a trial of risperidone 0.25 mg at bedtime to assist with sleep and behavior.

Was this prescription a wise decision? What other questions should this physician have asked?

Understanding the behavioral symptoms

Noncognitive symptoms of dementia, sometimes referred to as behavioral and psychological symptoms, are common, affecting almost 90% of patients with dementia,1-3 which itself can be classified as early, intermediate, and late.

In early dementia, sociability is usually not affected, but patients may repeat questions, misplace items, use poor judgment, and begin to have difficulty with more complex daily tasks like finances and driving.

In intermediate dementia, basic activities of daily living become impaired and normal social and environmental cues may not register.

In late dementia, patients become entirely dependent on others; they may lose the ability to speak, walk, and eventually, eat. Long- and short-term memory is lost.

Behavioral symptoms most often occur when the condition enters the intermediate phase, but they may occur at any time during the course of the disease.4 Behaviors may include refusal of care, yelling, aggressive behavior, agitation, restlessness, reversal of the normal sleep-wake cycle, wandering, hoarding, sexual disinhibition, culturally inappropriate behaviors, hallucinations, delusions, anxiety, depression, apathy, and psychosis.2,5

Behavioral disturbances often overwhelm families, and lack of treatment increases patient morbidity, may result in physical harm, and almost always precipitates institutionalization.2 Dementia-related behavioral disturbances also increase the risk of caregiver burnout and depression.2

These symptoms are difficult to treat with medications or nonpharmacologic therapy and strong evidence for most therapies is lacking. Physicians have historically prescribed either typical or atypical antipsychotics in an attempt to control these behaviors. In fact, medication is often still considered first-line therapy.6,7

CASE Ms. M’s daughter calls the clinic 2 weeks after the initial visit to tell the physician that her mother has been sleeping much better, but had a fall and was admitted to the hospital for a hip fracture. That’s not surprising; typical and atypical antipsychotics increase the risk of falls in the elderly.8

The risks associated with the use of antipsychotics

In 2005, the US Food and Drug Administration (FDA) issued a black box warning for atypical antipsychotics because they were found to increase mortality in the elderly. The increased mortality is due to cardiac events or infection.9,10 In 2008, the FDA warning was added to typical antipsychotics, as well.11,12 Both typical and atypical antipsychotics have been found to increase the risk of falls and strokes in the elderly,8,13 and their efficacy in treating the behavioral and psychological symptoms of dementia has recently been questioned.13-16

Trazodone and medications approved for the specific treatment of cognitive decline, such as donepezil or memantine, are also prescribed for behavioral disturbances, but evidence to support their efficacy is limited.14,17-20 More recently, a meta-analysis of selective serotonin reuptake inhibitors (SSRIs) suggests that they may be effective for treating agitation associated with dementia.21 However, SSRIs may also contribute to falls and to hyponatremia in the elderly.22,23

Pharmacologic Tx is not your only option

Considering the questionable safety and efficacy of pharmacologic treatment, physicians should consider nondrug therapies first, or at least concurrently with medication.2,15,16,24

But before you get started, be sure to look for and treat medical conditions that cause or contribute to behavioral disturbances, including infection, pain, and adverse effects of medication.6,7,25 Similarly, it is essential that unmet needs, such as hunger, thirst, or desire for attention or socialization, be addressed.6,7,26 Also, discuss disturbing environmental factors, including loud noises, poorly lit quarters, and strong smells, with patients and their caregivers.5-7 In complex situations, you may need to seek assistance from a geriatrician, neurologist, geropsychiatrist, or psychologist, although their availability may be limited.6

 

 

CASE Ms. M becomes markedly delirious while in the hospital after hip surgery, and a geriatrics consultation is requested. This is not surprising, given that underlying dementia increases a patient’s risk of delirium in the hospital.27 The geriatrician recommends several measures to reduce the likelihood of delirium—providing good pain control, minimizing night time wake-ups, minimizing Foley catheter use, Hep-locking the IV to encourage mobility, and having staff reorient her frequently by referring to a large print clock and calendar on the wall.

Specific interventions

Most specific nonpharmacologic therapies have not been robustly studied in randomized controlled trials. But a series of smaller studies have been evaluated in systematic reviews. The level of evidence for each intervention is summarized in TABLE 1.28-40

As you review the options that follow, keep 2 things in mind: (1) It is important to set realistic expectations when considering these approaches (as well as pharmacologic ones). Reducing the frequency or severity of problematic behaviors may be more reasonable than their total elimination.6,25 (2) Consider targeting specific symptoms when treating behavioral  Behavioral symptoms most often occur when dementia enters the intermediate phase, but they may occur at any time during the course of the disease. disturbances.2,24,41 Such targeting allows physicians and families to better evaluate the effectiveness of interventions because it helps to focus the discussion of the patient’s progress at follow-up visits.

Massage/touch therapy. A 2006 Cochrane review concluded that improvement in nutritional intake and hand massage, when combined with positive encouragement during a meal, may produce a short-term positive effect on agitation.29 Similarly, a meta-analysis of randomized controlled and randomized crossover studies found a statistically significant improvement in agitation with hand massage, although this finding was based on the same single study referenced in the 2006 review.30 Opinions differ among 5 high-quality guidelines included in the systematic review by Azermai et al regarding the value of massage, with 2 of the 5 practice guidelines recommending its use.28

Aromatherapy. Several trials suggest that aroma therapy may reduce agitated behaviors. Lemon balm and lavender oils have been the most commonly studied agents. Two systematic reviews cite the same 2002 randomized controlled trial, which found a reduction in behavioral problems in people who received arm massage with lemon balm compared with those who received arm massage with an odorless cream.30,31 A systematic review by Holt et al also cites a study that found lavender oil placed in a sachet on each side of the pillow for at least one hour during sleep seemed to reduce problem behaviors.31 Several evidence-based guidelines have concluded that aromatherapy may be helpful, and 2 of the 5 practice guidelines reviewed by Azermai et al recommend it.28

Exercise has been shown to benefit patients of all ages, even those with terminal diseases.42 Some studies have indicated a positive effect of physical activities on behaviors ranging from wandering to aggression and agitation. Activities have included group gentle stretches, indoor exercises, and a volunteer-led walking program that encouraged hand holding and singing.34 However, a 2008 Cochrane review concluded that the effect of exercise on behavioral disturbances in dementia has not been adequately studied.35

Music therapy. Numerous types of music therapy have been studied, including listening to music picked out by a patient’s family based on known patient preference, classical music, pleasant sounds such as ocean waves, and even stories and comforting prayer recorded by family members. While most of these smaller studies yielded positive results,34 a 2003 Cochrane review concluded there is not enough evidence to recommend for or against music therapy.43 A more recent meta-analysis suggests that music may be effective for agitation.30 A systematic review of quality guidelines also indicates that most of these guidelines rate the evidence as moderate to high in favor of music and 3 of 5 practice guidelines recommend it.28

Nonphysical barriers have long been used as a creative nonrestraining method of preventing wandering. They include such tricks as camouflaging exits by painting them to look like bookcases, painting a black square in front of an elevator to make it look like a hole, and placing a thin Velcro strip across doorways. Although it would appear from a limited number of small studies and anecdotal evidence that nonphysical barriers work, a Cochrane review concluded that they have not been studied enough to perform a meta-analysis.36

Cognitive stimulation typically consists of activities such as reviewing current events, promoting sensory awareness, drawing, associating words, discussion of hobbies, and planning daily activities. This type of therapy has been shown to improve cognition in patients with dementia, as well as well-being and quality of life. It does not improve behavioral problems, per se.37

 

 

Reminiscence therapy is a popular modality that involves stimulating memories of the past by looking at personal photos and newspaper clippings and discussing the past. It is well received by patients and caregivers. It has been shown to improve mood in elderly patients without dementia, but studies of reminiscence therapy have been too dissimilar to draw conclusions regarding its effect on behavioral disturbances in patients with dementia.38

Other therapies that are common in dementia care, such as respite care and specialized dementia units, have simply not been studied well enough to provide any conclusions as to their effectiveness.39,40

CASE When Ms. M is discharged from the hospital, her family enrolls her in an adult day care program, where Ms. M will be able to participate in social activities, exercise, and communal meals. Her daughter asks the family physician what other steps they can take in the home to make things easier on her mother. And as an aside, the daughter admits that while she is glad that she and her family can “be there” for her mother, there have been times when she has simply not felt up to the task.

Help family members care for the patient—and themselves

A recent meta-analysis suggests that caregiver interventions have a positive effect on behavioral problems in patients with dementia.32 Successful programs are tailored to the individual needs of the patient and caregiver and delivered over multiple sessions. Unfortunately, the aforementioned meta-analysis did not provide evidenced-based interventions for specific problems.32 With this in mind, the following are some practical caregiver “do’s and don’ts” that are based on reviews and consensus guidelines.

Don’t take it personally. It is extremely important to help caregivers understand that the disturbing behaviors of patients with dementia lack intentionality and are part of the normal progression of the disorder.25 Caregivers also need to appreciate that hallucinations are normal in these patients and do not require medications if they don’t disturb the patient or place the patient or anyone else at risk.

Don’t try to reason with the patient; redirect him or her instead. Clinicians should offer caregivers suggestions for reassuring, redirecting, or distracting agitated patients rather than trying to reason with them. Encourage caregivers to develop and maintain routines and consistency.6,25 Using a calm, low tone of voice, giving very simple instructions, and leaving and then reattempting care that is refused the first time may also be effective.5 Some experts have suggested techniques such as giving positive rewards for desired behaviors and not rewarding negative behaviors.6,26

Do create a safe environment. Recommend that caregivers create a safe environment. Make sure that they lock up all guns. Also, encourage them to use locks, alarms, or ID bracelets when patients are prone to wandering.25

Do consider a caregiver support program. Caregivers can make a big difference in the lives of patients with dementia, Help caregivers understand that the disturbing behaviors of patients with dementia lack intentionality and are part of the normal progression of the disorder. but only if they have support, as well.

A recent meta-analysis concluded that active involvement of caregivers in making choices about treatments distinguishes effective from ineffective support programs, decreases the odds of institutionalization, and may lengthen time to institutionalization.33 To ease caregiver strain and depression, encourage them to make use of resources such as nursing home respite care and community agencies that include the Alzheimer’s Association (http://www.alz.org).6,44,45

CASEMs. M’s daughter joins a local support group for families of patients with dementia, where she learns redirection techniques to try when her mother refuses care. The exercise and daytime social stimulation that Ms. M receives through the adult day care program helps her to sleep at night. When Ms. M refuses to take a shower—a challenge the family had before her hospitalization—the daughter does not argue with her. Instead, she returns 10 to 20 minutes later and asks again, or tries a bedside sponge bath with a lavender soap that Ms. M seems to like.

Ms. M’s nighttime wandering is markedly reduced and the family no longer uses any antipsychotic medications. The family physician counsels them, however, about the progressive nature of the disease and encourages them to set up periodic follow-up visits, so that he can see how everyone—patient and caregivers alike—are doing.

Welcoming the reprieves, recognizing the realities

The behavioral and psychological symptoms of dementia are the most challenging aspect of dementia care. Unacceptable behaviors sometimes persist even when aggressively addressing modifiable factors and attempting behavioral interventions (TABLE 2).2,5-7,15,16,24-26,32,41,44-46 Patients with behavioral disturbances frequently require a pharmacologic agent or transfer to a different care setting.

 

 

But clinicians need to use psychotropic medications with informed patient and/or caregiver consent.7 On a case-by-case basis, a trial of antipsychotics is often justified, despite the black box warning. A family may choose to try an antipsychotic despite the risk to help manage the patient at home in the hope of delaying or preventing institutionalization.

However, even with good home support, in conjunction with nonpharmacologic and/or pharmacologic therapies, most patients with dementia will eventually require institutionalization.47 Because patients and families often rely on family physicians to guide them through these difficult challenges and decisions, you’ll need to remain well versed on the available On a case-by- case basis, a trial of antipsychotics is often justified, despite the black box warning. treatments for the psychological and behavioral symptoms of dementia, as well as the resources available in your community.

CORRESPONDENCE
Jaqueline Raetz, MD, 331 NE Thornton Place, Seattle, WA 98125; jraetz@u.washington.edu

References

1. Mega MS, Cummings JL, Fiorello T, et al. The spectrum of behavioral changes in Alzheimer’s disease. Neurology. 1996;46:130-135.

2. Feil DG, MacLean C, Sultzer D. Quality indicators for the care of dementia in vulnerable elders. J Am Geriatr Soc. 2007;55(suppl 2):S293-S301.

3. Hort J, O’Brien JT, Gainotti G, et al. EFNS guidelines for the diagnosis and management of Alzheimer’s disease. Eur J Neurol. 2010;17:1236-1248.

4. Lyketsos CG, Lopez O, Jones B, et al. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA. 2002;288:1475-1483.

5. Omelan C. Approach to managing behavioural disturbances in dementia. Can Fam Physician. 2006;52:191-199.

6. Sadowsky CH, Galvin JE. Guidelines for the management of cognitive and behavioral problems in dementia. J Am Board Fam Med. 2012;25:350-366.

7. Salzman C, Jeste DV, Meyer RE, et al. Elderly patients with dementia-related symptoms of severe agitation and aggression: consensus statement on treatment options, clinical trials methodology, and policy. J Clin Psychiatry. 2008;69:889-898.

8. Hill KD, Wee R. Psychotropic drug-induced falls in older people: a review of interventions aimed at reducing the problem. Drugs Aging. 2012;29:15-30.

9. US Food and Drug Administration. Public health advisory: deaths with antipsychotics in elderly patients with behavioral disturbances. April 11, 2005. Available at:  http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm053171.htm. Accessed September 16, 2013.

10. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294:1934-1943.

11. US Food and Drug Administration. Antipsychotics, conventional and atypical. June 16, 2008. Available at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm110212.htm. Accessed September 16, 2013. 

12. Wang PS, Schneeweiss S, Avorn J, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med. 2005;353:2335-2341.

13. Ballard C, Waite J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer’s disease. Cochrane Database Syst Rev. 2006;(1):CD003476.

14. Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA. 2005;293:596-608.

15. Lonergan E, Luxenberg J, Colford JM. Haloperidol for agitation in dementia. Cochrane Database Syst Rev. 2002;(2):CD002852.

16. Schneider LS, Tariot PN, Dagerman KS, et al; CATIE-AD Study Group. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer’s disease. N Engl J Med. 2006;355:1525-1538.

17. Martinón-Torres G, Fioravanti M, Grimley EJ. Trazodone for agitation in dementia. Cochrane Database Syst Rev. 2004;(4):CD004990.

18. Birks J, Harvey RJ. Donepezil for dementia due to Alzheimer’s disease. Cochrane Database Syst Rev. 2006;(1):CD001190. 

19. McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev. 2006;(2):CD003154.

20. Raina P, Santaguida P, Ismaila A, et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med. 2008;148:379-397. 

21. Seitz DP, Adunuri N, Gill SS, et al. Antidepressants for agitation and psychosis in dementia. Cochrane Database Syst Rev. 2011;(2): CD008191.

22. Sterke CS, Ziere G, van Beeck EF, et al. Dose-response relationship between selective serotonin re-uptake inhibitors and injurious falls: a study in nursing home residents with dementia. Br J Clin Pharmacol. 2012;73:812-820.

23. Jacob S, Spinler SA. Hyponatremia associated with selective serotonin-reuptake inhibitors in older adults. Ann Pharmacother. 2006;40:1618-1622. 

24. Segal-Gidan F, Cherry D, Jones R, et al. Alzheimer’s disease management guideline: update 2008. Alzheimers Dement. 2011;7:e51-e59.

25. Rayner A, O’Brien J, Shoenbachler B. Behavior disorders of dementia: recognition and treatment. Am Fam Physician. 2006;73:647-652.

26. Ayalon L, Gum AM, Feliciano L, et al. Effectiveness of nonpharmacological interventions for the management of neuropsychiatric symptoms in patients with dementia: a systematic review. Arch Intern Med. 2006;166:2182-2188.

27. Elie M, Cole MG, Primeau FJ, et al. Delirium risk factors in elderly hospitalized patients. J Gen Intern Med. 1998;13:204-212.

28. Azermai M, Petrovic M, Elseviers MM, et al. Systematic appraisal of dementia guidelines for the management of behavioural and psychological symptoms. Aging Res Rev. 2012;11:78-86.

29. Viggo Hansen N, Jørgensen T, Ørtenblad L. Massage and touch for dementia. Cochrane Database Syst Rev. 2006;(4):CD004989.

30. Kong EH, Evans LK, Guevara JP. Nonpharmacological intervention for agitation in dementia: a systematic review and meta-analysis. Aging Ment Health. 2009;13:512-520.

31. Thorgrimsen LM, Spector A, Wiles A, et al. Aroma therapy for dementia. Cochrane Database Syst Rev. 2003;(3):CD003150.

32. Brodaty H, Arasaratnam C. Review of meta-analysis of nonpharmacological interventions for neuropsychiatric symptoms of dementia. Am J Psychiatry 2012;169:946-953.

33. Spijker A, Vernooij-Dassen M, Vasse E, et al. Effectiveness of nonpharmacological interventions in delaying the institutionalization of patients with dementia: A meta-analysis. J Am Geriatr Soc. 2008;56:1116-1128.

34. Opie J, Rosewarne R, O’Connor DW. The efficacy of psychosocial approaches to behaviour disorders in dementia: a systematic literature review. Aust N Z J Psychiatry. 1999;33:789-799.

35. Forbes D, Forbes S, Morgan DG, et al. Physical activity programs for persons with dementia. Cochrane Database Syst Rev. 2008;(3):CD006489.

36. Price JD, Hermans DG, Grimley Evans J. Subjective barriers to prevent wandering of cognitively impaired people. Cochrane Database Syst Rev. 2000;(4):CD001932.

37. Woods B, Aguirre E, Spector AE, et al. Cognitive stimulation to improve cognitive functioning in people with dementia. Cochrane Database Syst Rev. 2012;(2):CD005562.

38. Woods B, Spector A, Jones C, et al. Reminiscence therapy for dementia. Cochrane Database Syst Rev. 2005;(2):CD001120.

39. Lee H, Cameron M. Respite care for people with dementia and their carers. Cochrane Database Syst Rev. 2004;(2):CD004396.

40. Lai CK, Yeung JH, Mok V, et al. Special care units for dementia individuals with behavioural problems. Cochrane Database Syst Rev. 2009;(4):CD006470.

41. Waldemar G, Dubois B, Emre M, et al. Recommendations for the diagnosis and management of Alzheimer’s disease and other disorders associated with dementia: EFNS guideline. Eur J Neurol. 2007;14:e1-e26.

42. Oldervoll LM, Loge JH, Paltiel H, et al. The effect of a physical exercise program in palliative care: a phase II study. J Pain Symptom Manage. 2006;31:421-430.

43. Vink AC, Birks JS, Bruinsma MS, et al. Music therapy for people with dementia. Cochrane Database Syst Rev. 2004;(3):CD003477.

44. Gitlin LN, Kales HC, Lyketsos CG. Nonpharmacologic management of behavioral symptoms in dementia. JAMA. 2012;308:2020-2029.

45. Bass DM, Clark PA, Looman WJ, et al. The Cleveland Alzheimer’s managed care demonstration: outcomes after 12 months of implementation. Gerontologist. 2003;43:73-85.

46. Gitlin LN, Winter L, Dennis MP, et al.. A biobehavioral home-based intervention and the well-being of patients with dementia and their caregivers: the COPE randomized trial. JAMA. 2010;304:983-991.

47. Smith GE, Kokmen E, O’Brien PC. Risk factors for nursing home placement in a population-based dementia cohort. J Am Geriatr Soc. 2000;48:519-525.

Article PDF
Author and Disclosure Information

Jaqueline Raetz, MD
University of Washington, Department of Family Medicine, Seattle, Wash
jraetz@u.washington.edu

The author reported no potential conflict of interest relevant to this article.

Issue
The Journal of Family Practice - 62(10)
Publications
Topics
Page Number
548, 550-554,557
Legacy Keywords
Jaqueline Raetz; MD; dementia; antipsychotics; behavioral symptoms; nonpharmaceutical interventions; psychological symptoms; nondrug; Applied Evidence
Sections
Author and Disclosure Information

Jaqueline Raetz, MD
University of Washington, Department of Family Medicine, Seattle, Wash
jraetz@u.washington.edu

The author reported no potential conflict of interest relevant to this article.

Author and Disclosure Information

Jaqueline Raetz, MD
University of Washington, Department of Family Medicine, Seattle, Wash
jraetz@u.washington.edu

The author reported no potential conflict of interest relevant to this article.

Article PDF
Article PDF

Practice recommendations

› Attempt nonpharmacologic treatment for dementia behavioral problems before moving on to medications, which are of questionable efficacy for symptoms other than aggression and psychosis. A
› Obtain informed consent from patients and/or their caregivers if you plan to use antipsychotic medications because their use increases morbidity and mortality in the elderly. A

Strength of recommendation (SOR)

A Good-quality patient-oriented evidence
B Inconsistent or limited-quality patient-oriented evidence
C Consensus, usual practice, opinion, disease-oriented evidence, case series

CASE Ms. M, 86 years old, lives with her daughter, son-in-law, and granddaughter. For several years she has been forgetful, but she has never had a formal work-up for dementia. Her daughter finally brings her to their primary care physician because she was refusing to take showers, was increasingly irritable, and had tried to hit her daughter’s husband.

In the office, however, Ms. M is calm and pleasant. The family says that most nights Ms. M gets up and wanders around the house. She denies feeling depressed or anxious, but her Folstein Mini-Mental State Exam score is 22/30, indicating moderate dementia. (For more on assessment, see “Tools for assessing patients with dementia—and their caregivers” on page 552.)

The physician offers a trial of risperidone 0.25 mg at bedtime to assist with sleep and behavior.

Was this prescription a wise decision? What other questions should this physician have asked?

Understanding the behavioral symptoms

Noncognitive symptoms of dementia, sometimes referred to as behavioral and psychological symptoms, are common, affecting almost 90% of patients with dementia,1-3 which itself can be classified as early, intermediate, and late.

In early dementia, sociability is usually not affected, but patients may repeat questions, misplace items, use poor judgment, and begin to have difficulty with more complex daily tasks like finances and driving.

In intermediate dementia, basic activities of daily living become impaired and normal social and environmental cues may not register.

In late dementia, patients become entirely dependent on others; they may lose the ability to speak, walk, and eventually, eat. Long- and short-term memory is lost.

Behavioral symptoms most often occur when the condition enters the intermediate phase, but they may occur at any time during the course of the disease.4 Behaviors may include refusal of care, yelling, aggressive behavior, agitation, restlessness, reversal of the normal sleep-wake cycle, wandering, hoarding, sexual disinhibition, culturally inappropriate behaviors, hallucinations, delusions, anxiety, depression, apathy, and psychosis.2,5

Behavioral disturbances often overwhelm families, and lack of treatment increases patient morbidity, may result in physical harm, and almost always precipitates institutionalization.2 Dementia-related behavioral disturbances also increase the risk of caregiver burnout and depression.2

These symptoms are difficult to treat with medications or nonpharmacologic therapy and strong evidence for most therapies is lacking. Physicians have historically prescribed either typical or atypical antipsychotics in an attempt to control these behaviors. In fact, medication is often still considered first-line therapy.6,7

CASE Ms. M’s daughter calls the clinic 2 weeks after the initial visit to tell the physician that her mother has been sleeping much better, but had a fall and was admitted to the hospital for a hip fracture. That’s not surprising; typical and atypical antipsychotics increase the risk of falls in the elderly.8

The risks associated with the use of antipsychotics

In 2005, the US Food and Drug Administration (FDA) issued a black box warning for atypical antipsychotics because they were found to increase mortality in the elderly. The increased mortality is due to cardiac events or infection.9,10 In 2008, the FDA warning was added to typical antipsychotics, as well.11,12 Both typical and atypical antipsychotics have been found to increase the risk of falls and strokes in the elderly,8,13 and their efficacy in treating the behavioral and psychological symptoms of dementia has recently been questioned.13-16

Trazodone and medications approved for the specific treatment of cognitive decline, such as donepezil or memantine, are also prescribed for behavioral disturbances, but evidence to support their efficacy is limited.14,17-20 More recently, a meta-analysis of selective serotonin reuptake inhibitors (SSRIs) suggests that they may be effective for treating agitation associated with dementia.21 However, SSRIs may also contribute to falls and to hyponatremia in the elderly.22,23

Pharmacologic Tx is not your only option

Considering the questionable safety and efficacy of pharmacologic treatment, physicians should consider nondrug therapies first, or at least concurrently with medication.2,15,16,24

But before you get started, be sure to look for and treat medical conditions that cause or contribute to behavioral disturbances, including infection, pain, and adverse effects of medication.6,7,25 Similarly, it is essential that unmet needs, such as hunger, thirst, or desire for attention or socialization, be addressed.6,7,26 Also, discuss disturbing environmental factors, including loud noises, poorly lit quarters, and strong smells, with patients and their caregivers.5-7 In complex situations, you may need to seek assistance from a geriatrician, neurologist, geropsychiatrist, or psychologist, although their availability may be limited.6

 

 

CASE Ms. M becomes markedly delirious while in the hospital after hip surgery, and a geriatrics consultation is requested. This is not surprising, given that underlying dementia increases a patient’s risk of delirium in the hospital.27 The geriatrician recommends several measures to reduce the likelihood of delirium—providing good pain control, minimizing night time wake-ups, minimizing Foley catheter use, Hep-locking the IV to encourage mobility, and having staff reorient her frequently by referring to a large print clock and calendar on the wall.

Specific interventions

Most specific nonpharmacologic therapies have not been robustly studied in randomized controlled trials. But a series of smaller studies have been evaluated in systematic reviews. The level of evidence for each intervention is summarized in TABLE 1.28-40

As you review the options that follow, keep 2 things in mind: (1) It is important to set realistic expectations when considering these approaches (as well as pharmacologic ones). Reducing the frequency or severity of problematic behaviors may be more reasonable than their total elimination.6,25 (2) Consider targeting specific symptoms when treating behavioral  Behavioral symptoms most often occur when dementia enters the intermediate phase, but they may occur at any time during the course of the disease. disturbances.2,24,41 Such targeting allows physicians and families to better evaluate the effectiveness of interventions because it helps to focus the discussion of the patient’s progress at follow-up visits.

Massage/touch therapy. A 2006 Cochrane review concluded that improvement in nutritional intake and hand massage, when combined with positive encouragement during a meal, may produce a short-term positive effect on agitation.29 Similarly, a meta-analysis of randomized controlled and randomized crossover studies found a statistically significant improvement in agitation with hand massage, although this finding was based on the same single study referenced in the 2006 review.30 Opinions differ among 5 high-quality guidelines included in the systematic review by Azermai et al regarding the value of massage, with 2 of the 5 practice guidelines recommending its use.28

Aromatherapy. Several trials suggest that aroma therapy may reduce agitated behaviors. Lemon balm and lavender oils have been the most commonly studied agents. Two systematic reviews cite the same 2002 randomized controlled trial, which found a reduction in behavioral problems in people who received arm massage with lemon balm compared with those who received arm massage with an odorless cream.30,31 A systematic review by Holt et al also cites a study that found lavender oil placed in a sachet on each side of the pillow for at least one hour during sleep seemed to reduce problem behaviors.31 Several evidence-based guidelines have concluded that aromatherapy may be helpful, and 2 of the 5 practice guidelines reviewed by Azermai et al recommend it.28

Exercise has been shown to benefit patients of all ages, even those with terminal diseases.42 Some studies have indicated a positive effect of physical activities on behaviors ranging from wandering to aggression and agitation. Activities have included group gentle stretches, indoor exercises, and a volunteer-led walking program that encouraged hand holding and singing.34 However, a 2008 Cochrane review concluded that the effect of exercise on behavioral disturbances in dementia has not been adequately studied.35

Music therapy. Numerous types of music therapy have been studied, including listening to music picked out by a patient’s family based on known patient preference, classical music, pleasant sounds such as ocean waves, and even stories and comforting prayer recorded by family members. While most of these smaller studies yielded positive results,34 a 2003 Cochrane review concluded there is not enough evidence to recommend for or against music therapy.43 A more recent meta-analysis suggests that music may be effective for agitation.30 A systematic review of quality guidelines also indicates that most of these guidelines rate the evidence as moderate to high in favor of music and 3 of 5 practice guidelines recommend it.28

Nonphysical barriers have long been used as a creative nonrestraining method of preventing wandering. They include such tricks as camouflaging exits by painting them to look like bookcases, painting a black square in front of an elevator to make it look like a hole, and placing a thin Velcro strip across doorways. Although it would appear from a limited number of small studies and anecdotal evidence that nonphysical barriers work, a Cochrane review concluded that they have not been studied enough to perform a meta-analysis.36

Cognitive stimulation typically consists of activities such as reviewing current events, promoting sensory awareness, drawing, associating words, discussion of hobbies, and planning daily activities. This type of therapy has been shown to improve cognition in patients with dementia, as well as well-being and quality of life. It does not improve behavioral problems, per se.37

 

 

Reminiscence therapy is a popular modality that involves stimulating memories of the past by looking at personal photos and newspaper clippings and discussing the past. It is well received by patients and caregivers. It has been shown to improve mood in elderly patients without dementia, but studies of reminiscence therapy have been too dissimilar to draw conclusions regarding its effect on behavioral disturbances in patients with dementia.38

Other therapies that are common in dementia care, such as respite care and specialized dementia units, have simply not been studied well enough to provide any conclusions as to their effectiveness.39,40

CASE When Ms. M is discharged from the hospital, her family enrolls her in an adult day care program, where Ms. M will be able to participate in social activities, exercise, and communal meals. Her daughter asks the family physician what other steps they can take in the home to make things easier on her mother. And as an aside, the daughter admits that while she is glad that she and her family can “be there” for her mother, there have been times when she has simply not felt up to the task.

Help family members care for the patient—and themselves

A recent meta-analysis suggests that caregiver interventions have a positive effect on behavioral problems in patients with dementia.32 Successful programs are tailored to the individual needs of the patient and caregiver and delivered over multiple sessions. Unfortunately, the aforementioned meta-analysis did not provide evidenced-based interventions for specific problems.32 With this in mind, the following are some practical caregiver “do’s and don’ts” that are based on reviews and consensus guidelines.

Don’t take it personally. It is extremely important to help caregivers understand that the disturbing behaviors of patients with dementia lack intentionality and are part of the normal progression of the disorder.25 Caregivers also need to appreciate that hallucinations are normal in these patients and do not require medications if they don’t disturb the patient or place the patient or anyone else at risk.

Don’t try to reason with the patient; redirect him or her instead. Clinicians should offer caregivers suggestions for reassuring, redirecting, or distracting agitated patients rather than trying to reason with them. Encourage caregivers to develop and maintain routines and consistency.6,25 Using a calm, low tone of voice, giving very simple instructions, and leaving and then reattempting care that is refused the first time may also be effective.5 Some experts have suggested techniques such as giving positive rewards for desired behaviors and not rewarding negative behaviors.6,26

Do create a safe environment. Recommend that caregivers create a safe environment. Make sure that they lock up all guns. Also, encourage them to use locks, alarms, or ID bracelets when patients are prone to wandering.25

Do consider a caregiver support program. Caregivers can make a big difference in the lives of patients with dementia, Help caregivers understand that the disturbing behaviors of patients with dementia lack intentionality and are part of the normal progression of the disorder. but only if they have support, as well.

A recent meta-analysis concluded that active involvement of caregivers in making choices about treatments distinguishes effective from ineffective support programs, decreases the odds of institutionalization, and may lengthen time to institutionalization.33 To ease caregiver strain and depression, encourage them to make use of resources such as nursing home respite care and community agencies that include the Alzheimer’s Association (http://www.alz.org).6,44,45

CASEMs. M’s daughter joins a local support group for families of patients with dementia, where she learns redirection techniques to try when her mother refuses care. The exercise and daytime social stimulation that Ms. M receives through the adult day care program helps her to sleep at night. When Ms. M refuses to take a shower—a challenge the family had before her hospitalization—the daughter does not argue with her. Instead, she returns 10 to 20 minutes later and asks again, or tries a bedside sponge bath with a lavender soap that Ms. M seems to like.

Ms. M’s nighttime wandering is markedly reduced and the family no longer uses any antipsychotic medications. The family physician counsels them, however, about the progressive nature of the disease and encourages them to set up periodic follow-up visits, so that he can see how everyone—patient and caregivers alike—are doing.

Welcoming the reprieves, recognizing the realities

The behavioral and psychological symptoms of dementia are the most challenging aspect of dementia care. Unacceptable behaviors sometimes persist even when aggressively addressing modifiable factors and attempting behavioral interventions (TABLE 2).2,5-7,15,16,24-26,32,41,44-46 Patients with behavioral disturbances frequently require a pharmacologic agent or transfer to a different care setting.

 

 

But clinicians need to use psychotropic medications with informed patient and/or caregiver consent.7 On a case-by-case basis, a trial of antipsychotics is often justified, despite the black box warning. A family may choose to try an antipsychotic despite the risk to help manage the patient at home in the hope of delaying or preventing institutionalization.

However, even with good home support, in conjunction with nonpharmacologic and/or pharmacologic therapies, most patients with dementia will eventually require institutionalization.47 Because patients and families often rely on family physicians to guide them through these difficult challenges and decisions, you’ll need to remain well versed on the available On a case-by- case basis, a trial of antipsychotics is often justified, despite the black box warning. treatments for the psychological and behavioral symptoms of dementia, as well as the resources available in your community.

CORRESPONDENCE
Jaqueline Raetz, MD, 331 NE Thornton Place, Seattle, WA 98125; jraetz@u.washington.edu

Practice recommendations

› Attempt nonpharmacologic treatment for dementia behavioral problems before moving on to medications, which are of questionable efficacy for symptoms other than aggression and psychosis. A
› Obtain informed consent from patients and/or their caregivers if you plan to use antipsychotic medications because their use increases morbidity and mortality in the elderly. A

Strength of recommendation (SOR)

A Good-quality patient-oriented evidence
B Inconsistent or limited-quality patient-oriented evidence
C Consensus, usual practice, opinion, disease-oriented evidence, case series

CASE Ms. M, 86 years old, lives with her daughter, son-in-law, and granddaughter. For several years she has been forgetful, but she has never had a formal work-up for dementia. Her daughter finally brings her to their primary care physician because she was refusing to take showers, was increasingly irritable, and had tried to hit her daughter’s husband.

In the office, however, Ms. M is calm and pleasant. The family says that most nights Ms. M gets up and wanders around the house. She denies feeling depressed or anxious, but her Folstein Mini-Mental State Exam score is 22/30, indicating moderate dementia. (For more on assessment, see “Tools for assessing patients with dementia—and their caregivers” on page 552.)

The physician offers a trial of risperidone 0.25 mg at bedtime to assist with sleep and behavior.

Was this prescription a wise decision? What other questions should this physician have asked?

Understanding the behavioral symptoms

Noncognitive symptoms of dementia, sometimes referred to as behavioral and psychological symptoms, are common, affecting almost 90% of patients with dementia,1-3 which itself can be classified as early, intermediate, and late.

In early dementia, sociability is usually not affected, but patients may repeat questions, misplace items, use poor judgment, and begin to have difficulty with more complex daily tasks like finances and driving.

In intermediate dementia, basic activities of daily living become impaired and normal social and environmental cues may not register.

In late dementia, patients become entirely dependent on others; they may lose the ability to speak, walk, and eventually, eat. Long- and short-term memory is lost.

Behavioral symptoms most often occur when the condition enters the intermediate phase, but they may occur at any time during the course of the disease.4 Behaviors may include refusal of care, yelling, aggressive behavior, agitation, restlessness, reversal of the normal sleep-wake cycle, wandering, hoarding, sexual disinhibition, culturally inappropriate behaviors, hallucinations, delusions, anxiety, depression, apathy, and psychosis.2,5

Behavioral disturbances often overwhelm families, and lack of treatment increases patient morbidity, may result in physical harm, and almost always precipitates institutionalization.2 Dementia-related behavioral disturbances also increase the risk of caregiver burnout and depression.2

These symptoms are difficult to treat with medications or nonpharmacologic therapy and strong evidence for most therapies is lacking. Physicians have historically prescribed either typical or atypical antipsychotics in an attempt to control these behaviors. In fact, medication is often still considered first-line therapy.6,7

CASE Ms. M’s daughter calls the clinic 2 weeks after the initial visit to tell the physician that her mother has been sleeping much better, but had a fall and was admitted to the hospital for a hip fracture. That’s not surprising; typical and atypical antipsychotics increase the risk of falls in the elderly.8

The risks associated with the use of antipsychotics

In 2005, the US Food and Drug Administration (FDA) issued a black box warning for atypical antipsychotics because they were found to increase mortality in the elderly. The increased mortality is due to cardiac events or infection.9,10 In 2008, the FDA warning was added to typical antipsychotics, as well.11,12 Both typical and atypical antipsychotics have been found to increase the risk of falls and strokes in the elderly,8,13 and their efficacy in treating the behavioral and psychological symptoms of dementia has recently been questioned.13-16

Trazodone and medications approved for the specific treatment of cognitive decline, such as donepezil or memantine, are also prescribed for behavioral disturbances, but evidence to support their efficacy is limited.14,17-20 More recently, a meta-analysis of selective serotonin reuptake inhibitors (SSRIs) suggests that they may be effective for treating agitation associated with dementia.21 However, SSRIs may also contribute to falls and to hyponatremia in the elderly.22,23

Pharmacologic Tx is not your only option

Considering the questionable safety and efficacy of pharmacologic treatment, physicians should consider nondrug therapies first, or at least concurrently with medication.2,15,16,24

But before you get started, be sure to look for and treat medical conditions that cause or contribute to behavioral disturbances, including infection, pain, and adverse effects of medication.6,7,25 Similarly, it is essential that unmet needs, such as hunger, thirst, or desire for attention or socialization, be addressed.6,7,26 Also, discuss disturbing environmental factors, including loud noises, poorly lit quarters, and strong smells, with patients and their caregivers.5-7 In complex situations, you may need to seek assistance from a geriatrician, neurologist, geropsychiatrist, or psychologist, although their availability may be limited.6

 

 

CASE Ms. M becomes markedly delirious while in the hospital after hip surgery, and a geriatrics consultation is requested. This is not surprising, given that underlying dementia increases a patient’s risk of delirium in the hospital.27 The geriatrician recommends several measures to reduce the likelihood of delirium—providing good pain control, minimizing night time wake-ups, minimizing Foley catheter use, Hep-locking the IV to encourage mobility, and having staff reorient her frequently by referring to a large print clock and calendar on the wall.

Specific interventions

Most specific nonpharmacologic therapies have not been robustly studied in randomized controlled trials. But a series of smaller studies have been evaluated in systematic reviews. The level of evidence for each intervention is summarized in TABLE 1.28-40

As you review the options that follow, keep 2 things in mind: (1) It is important to set realistic expectations when considering these approaches (as well as pharmacologic ones). Reducing the frequency or severity of problematic behaviors may be more reasonable than their total elimination.6,25 (2) Consider targeting specific symptoms when treating behavioral  Behavioral symptoms most often occur when dementia enters the intermediate phase, but they may occur at any time during the course of the disease. disturbances.2,24,41 Such targeting allows physicians and families to better evaluate the effectiveness of interventions because it helps to focus the discussion of the patient’s progress at follow-up visits.

Massage/touch therapy. A 2006 Cochrane review concluded that improvement in nutritional intake and hand massage, when combined with positive encouragement during a meal, may produce a short-term positive effect on agitation.29 Similarly, a meta-analysis of randomized controlled and randomized crossover studies found a statistically significant improvement in agitation with hand massage, although this finding was based on the same single study referenced in the 2006 review.30 Opinions differ among 5 high-quality guidelines included in the systematic review by Azermai et al regarding the value of massage, with 2 of the 5 practice guidelines recommending its use.28

Aromatherapy. Several trials suggest that aroma therapy may reduce agitated behaviors. Lemon balm and lavender oils have been the most commonly studied agents. Two systematic reviews cite the same 2002 randomized controlled trial, which found a reduction in behavioral problems in people who received arm massage with lemon balm compared with those who received arm massage with an odorless cream.30,31 A systematic review by Holt et al also cites a study that found lavender oil placed in a sachet on each side of the pillow for at least one hour during sleep seemed to reduce problem behaviors.31 Several evidence-based guidelines have concluded that aromatherapy may be helpful, and 2 of the 5 practice guidelines reviewed by Azermai et al recommend it.28

Exercise has been shown to benefit patients of all ages, even those with terminal diseases.42 Some studies have indicated a positive effect of physical activities on behaviors ranging from wandering to aggression and agitation. Activities have included group gentle stretches, indoor exercises, and a volunteer-led walking program that encouraged hand holding and singing.34 However, a 2008 Cochrane review concluded that the effect of exercise on behavioral disturbances in dementia has not been adequately studied.35

Music therapy. Numerous types of music therapy have been studied, including listening to music picked out by a patient’s family based on known patient preference, classical music, pleasant sounds such as ocean waves, and even stories and comforting prayer recorded by family members. While most of these smaller studies yielded positive results,34 a 2003 Cochrane review concluded there is not enough evidence to recommend for or against music therapy.43 A more recent meta-analysis suggests that music may be effective for agitation.30 A systematic review of quality guidelines also indicates that most of these guidelines rate the evidence as moderate to high in favor of music and 3 of 5 practice guidelines recommend it.28

Nonphysical barriers have long been used as a creative nonrestraining method of preventing wandering. They include such tricks as camouflaging exits by painting them to look like bookcases, painting a black square in front of an elevator to make it look like a hole, and placing a thin Velcro strip across doorways. Although it would appear from a limited number of small studies and anecdotal evidence that nonphysical barriers work, a Cochrane review concluded that they have not been studied enough to perform a meta-analysis.36

Cognitive stimulation typically consists of activities such as reviewing current events, promoting sensory awareness, drawing, associating words, discussion of hobbies, and planning daily activities. This type of therapy has been shown to improve cognition in patients with dementia, as well as well-being and quality of life. It does not improve behavioral problems, per se.37

 

 

Reminiscence therapy is a popular modality that involves stimulating memories of the past by looking at personal photos and newspaper clippings and discussing the past. It is well received by patients and caregivers. It has been shown to improve mood in elderly patients without dementia, but studies of reminiscence therapy have been too dissimilar to draw conclusions regarding its effect on behavioral disturbances in patients with dementia.38

Other therapies that are common in dementia care, such as respite care and specialized dementia units, have simply not been studied well enough to provide any conclusions as to their effectiveness.39,40

CASE When Ms. M is discharged from the hospital, her family enrolls her in an adult day care program, where Ms. M will be able to participate in social activities, exercise, and communal meals. Her daughter asks the family physician what other steps they can take in the home to make things easier on her mother. And as an aside, the daughter admits that while she is glad that she and her family can “be there” for her mother, there have been times when she has simply not felt up to the task.

Help family members care for the patient—and themselves

A recent meta-analysis suggests that caregiver interventions have a positive effect on behavioral problems in patients with dementia.32 Successful programs are tailored to the individual needs of the patient and caregiver and delivered over multiple sessions. Unfortunately, the aforementioned meta-analysis did not provide evidenced-based interventions for specific problems.32 With this in mind, the following are some practical caregiver “do’s and don’ts” that are based on reviews and consensus guidelines.

Don’t take it personally. It is extremely important to help caregivers understand that the disturbing behaviors of patients with dementia lack intentionality and are part of the normal progression of the disorder.25 Caregivers also need to appreciate that hallucinations are normal in these patients and do not require medications if they don’t disturb the patient or place the patient or anyone else at risk.

Don’t try to reason with the patient; redirect him or her instead. Clinicians should offer caregivers suggestions for reassuring, redirecting, or distracting agitated patients rather than trying to reason with them. Encourage caregivers to develop and maintain routines and consistency.6,25 Using a calm, low tone of voice, giving very simple instructions, and leaving and then reattempting care that is refused the first time may also be effective.5 Some experts have suggested techniques such as giving positive rewards for desired behaviors and not rewarding negative behaviors.6,26

Do create a safe environment. Recommend that caregivers create a safe environment. Make sure that they lock up all guns. Also, encourage them to use locks, alarms, or ID bracelets when patients are prone to wandering.25

Do consider a caregiver support program. Caregivers can make a big difference in the lives of patients with dementia, Help caregivers understand that the disturbing behaviors of patients with dementia lack intentionality and are part of the normal progression of the disorder. but only if they have support, as well.

A recent meta-analysis concluded that active involvement of caregivers in making choices about treatments distinguishes effective from ineffective support programs, decreases the odds of institutionalization, and may lengthen time to institutionalization.33 To ease caregiver strain and depression, encourage them to make use of resources such as nursing home respite care and community agencies that include the Alzheimer’s Association (http://www.alz.org).6,44,45

CASEMs. M’s daughter joins a local support group for families of patients with dementia, where she learns redirection techniques to try when her mother refuses care. The exercise and daytime social stimulation that Ms. M receives through the adult day care program helps her to sleep at night. When Ms. M refuses to take a shower—a challenge the family had before her hospitalization—the daughter does not argue with her. Instead, she returns 10 to 20 minutes later and asks again, or tries a bedside sponge bath with a lavender soap that Ms. M seems to like.

Ms. M’s nighttime wandering is markedly reduced and the family no longer uses any antipsychotic medications. The family physician counsels them, however, about the progressive nature of the disease and encourages them to set up periodic follow-up visits, so that he can see how everyone—patient and caregivers alike—are doing.

Welcoming the reprieves, recognizing the realities

The behavioral and psychological symptoms of dementia are the most challenging aspect of dementia care. Unacceptable behaviors sometimes persist even when aggressively addressing modifiable factors and attempting behavioral interventions (TABLE 2).2,5-7,15,16,24-26,32,41,44-46 Patients with behavioral disturbances frequently require a pharmacologic agent or transfer to a different care setting.

 

 

But clinicians need to use psychotropic medications with informed patient and/or caregiver consent.7 On a case-by-case basis, a trial of antipsychotics is often justified, despite the black box warning. A family may choose to try an antipsychotic despite the risk to help manage the patient at home in the hope of delaying or preventing institutionalization.

However, even with good home support, in conjunction with nonpharmacologic and/or pharmacologic therapies, most patients with dementia will eventually require institutionalization.47 Because patients and families often rely on family physicians to guide them through these difficult challenges and decisions, you’ll need to remain well versed on the available On a case-by- case basis, a trial of antipsychotics is often justified, despite the black box warning. treatments for the psychological and behavioral symptoms of dementia, as well as the resources available in your community.

CORRESPONDENCE
Jaqueline Raetz, MD, 331 NE Thornton Place, Seattle, WA 98125; jraetz@u.washington.edu

References

1. Mega MS, Cummings JL, Fiorello T, et al. The spectrum of behavioral changes in Alzheimer’s disease. Neurology. 1996;46:130-135.

2. Feil DG, MacLean C, Sultzer D. Quality indicators for the care of dementia in vulnerable elders. J Am Geriatr Soc. 2007;55(suppl 2):S293-S301.

3. Hort J, O’Brien JT, Gainotti G, et al. EFNS guidelines for the diagnosis and management of Alzheimer’s disease. Eur J Neurol. 2010;17:1236-1248.

4. Lyketsos CG, Lopez O, Jones B, et al. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA. 2002;288:1475-1483.

5. Omelan C. Approach to managing behavioural disturbances in dementia. Can Fam Physician. 2006;52:191-199.

6. Sadowsky CH, Galvin JE. Guidelines for the management of cognitive and behavioral problems in dementia. J Am Board Fam Med. 2012;25:350-366.

7. Salzman C, Jeste DV, Meyer RE, et al. Elderly patients with dementia-related symptoms of severe agitation and aggression: consensus statement on treatment options, clinical trials methodology, and policy. J Clin Psychiatry. 2008;69:889-898.

8. Hill KD, Wee R. Psychotropic drug-induced falls in older people: a review of interventions aimed at reducing the problem. Drugs Aging. 2012;29:15-30.

9. US Food and Drug Administration. Public health advisory: deaths with antipsychotics in elderly patients with behavioral disturbances. April 11, 2005. Available at:  http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm053171.htm. Accessed September 16, 2013.

10. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294:1934-1943.

11. US Food and Drug Administration. Antipsychotics, conventional and atypical. June 16, 2008. Available at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm110212.htm. Accessed September 16, 2013. 

12. Wang PS, Schneeweiss S, Avorn J, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med. 2005;353:2335-2341.

13. Ballard C, Waite J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer’s disease. Cochrane Database Syst Rev. 2006;(1):CD003476.

14. Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA. 2005;293:596-608.

15. Lonergan E, Luxenberg J, Colford JM. Haloperidol for agitation in dementia. Cochrane Database Syst Rev. 2002;(2):CD002852.

16. Schneider LS, Tariot PN, Dagerman KS, et al; CATIE-AD Study Group. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer’s disease. N Engl J Med. 2006;355:1525-1538.

17. Martinón-Torres G, Fioravanti M, Grimley EJ. Trazodone for agitation in dementia. Cochrane Database Syst Rev. 2004;(4):CD004990.

18. Birks J, Harvey RJ. Donepezil for dementia due to Alzheimer’s disease. Cochrane Database Syst Rev. 2006;(1):CD001190. 

19. McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev. 2006;(2):CD003154.

20. Raina P, Santaguida P, Ismaila A, et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med. 2008;148:379-397. 

21. Seitz DP, Adunuri N, Gill SS, et al. Antidepressants for agitation and psychosis in dementia. Cochrane Database Syst Rev. 2011;(2): CD008191.

22. Sterke CS, Ziere G, van Beeck EF, et al. Dose-response relationship between selective serotonin re-uptake inhibitors and injurious falls: a study in nursing home residents with dementia. Br J Clin Pharmacol. 2012;73:812-820.

23. Jacob S, Spinler SA. Hyponatremia associated with selective serotonin-reuptake inhibitors in older adults. Ann Pharmacother. 2006;40:1618-1622. 

24. Segal-Gidan F, Cherry D, Jones R, et al. Alzheimer’s disease management guideline: update 2008. Alzheimers Dement. 2011;7:e51-e59.

25. Rayner A, O’Brien J, Shoenbachler B. Behavior disorders of dementia: recognition and treatment. Am Fam Physician. 2006;73:647-652.

26. Ayalon L, Gum AM, Feliciano L, et al. Effectiveness of nonpharmacological interventions for the management of neuropsychiatric symptoms in patients with dementia: a systematic review. Arch Intern Med. 2006;166:2182-2188.

27. Elie M, Cole MG, Primeau FJ, et al. Delirium risk factors in elderly hospitalized patients. J Gen Intern Med. 1998;13:204-212.

28. Azermai M, Petrovic M, Elseviers MM, et al. Systematic appraisal of dementia guidelines for the management of behavioural and psychological symptoms. Aging Res Rev. 2012;11:78-86.

29. Viggo Hansen N, Jørgensen T, Ørtenblad L. Massage and touch for dementia. Cochrane Database Syst Rev. 2006;(4):CD004989.

30. Kong EH, Evans LK, Guevara JP. Nonpharmacological intervention for agitation in dementia: a systematic review and meta-analysis. Aging Ment Health. 2009;13:512-520.

31. Thorgrimsen LM, Spector A, Wiles A, et al. Aroma therapy for dementia. Cochrane Database Syst Rev. 2003;(3):CD003150.

32. Brodaty H, Arasaratnam C. Review of meta-analysis of nonpharmacological interventions for neuropsychiatric symptoms of dementia. Am J Psychiatry 2012;169:946-953.

33. Spijker A, Vernooij-Dassen M, Vasse E, et al. Effectiveness of nonpharmacological interventions in delaying the institutionalization of patients with dementia: A meta-analysis. J Am Geriatr Soc. 2008;56:1116-1128.

34. Opie J, Rosewarne R, O’Connor DW. The efficacy of psychosocial approaches to behaviour disorders in dementia: a systematic literature review. Aust N Z J Psychiatry. 1999;33:789-799.

35. Forbes D, Forbes S, Morgan DG, et al. Physical activity programs for persons with dementia. Cochrane Database Syst Rev. 2008;(3):CD006489.

36. Price JD, Hermans DG, Grimley Evans J. Subjective barriers to prevent wandering of cognitively impaired people. Cochrane Database Syst Rev. 2000;(4):CD001932.

37. Woods B, Aguirre E, Spector AE, et al. Cognitive stimulation to improve cognitive functioning in people with dementia. Cochrane Database Syst Rev. 2012;(2):CD005562.

38. Woods B, Spector A, Jones C, et al. Reminiscence therapy for dementia. Cochrane Database Syst Rev. 2005;(2):CD001120.

39. Lee H, Cameron M. Respite care for people with dementia and their carers. Cochrane Database Syst Rev. 2004;(2):CD004396.

40. Lai CK, Yeung JH, Mok V, et al. Special care units for dementia individuals with behavioural problems. Cochrane Database Syst Rev. 2009;(4):CD006470.

41. Waldemar G, Dubois B, Emre M, et al. Recommendations for the diagnosis and management of Alzheimer’s disease and other disorders associated with dementia: EFNS guideline. Eur J Neurol. 2007;14:e1-e26.

42. Oldervoll LM, Loge JH, Paltiel H, et al. The effect of a physical exercise program in palliative care: a phase II study. J Pain Symptom Manage. 2006;31:421-430.

43. Vink AC, Birks JS, Bruinsma MS, et al. Music therapy for people with dementia. Cochrane Database Syst Rev. 2004;(3):CD003477.

44. Gitlin LN, Kales HC, Lyketsos CG. Nonpharmacologic management of behavioral symptoms in dementia. JAMA. 2012;308:2020-2029.

45. Bass DM, Clark PA, Looman WJ, et al. The Cleveland Alzheimer’s managed care demonstration: outcomes after 12 months of implementation. Gerontologist. 2003;43:73-85.

46. Gitlin LN, Winter L, Dennis MP, et al.. A biobehavioral home-based intervention and the well-being of patients with dementia and their caregivers: the COPE randomized trial. JAMA. 2010;304:983-991.

47. Smith GE, Kokmen E, O’Brien PC. Risk factors for nursing home placement in a population-based dementia cohort. J Am Geriatr Soc. 2000;48:519-525.

References

1. Mega MS, Cummings JL, Fiorello T, et al. The spectrum of behavioral changes in Alzheimer’s disease. Neurology. 1996;46:130-135.

2. Feil DG, MacLean C, Sultzer D. Quality indicators for the care of dementia in vulnerable elders. J Am Geriatr Soc. 2007;55(suppl 2):S293-S301.

3. Hort J, O’Brien JT, Gainotti G, et al. EFNS guidelines for the diagnosis and management of Alzheimer’s disease. Eur J Neurol. 2010;17:1236-1248.

4. Lyketsos CG, Lopez O, Jones B, et al. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA. 2002;288:1475-1483.

5. Omelan C. Approach to managing behavioural disturbances in dementia. Can Fam Physician. 2006;52:191-199.

6. Sadowsky CH, Galvin JE. Guidelines for the management of cognitive and behavioral problems in dementia. J Am Board Fam Med. 2012;25:350-366.

7. Salzman C, Jeste DV, Meyer RE, et al. Elderly patients with dementia-related symptoms of severe agitation and aggression: consensus statement on treatment options, clinical trials methodology, and policy. J Clin Psychiatry. 2008;69:889-898.

8. Hill KD, Wee R. Psychotropic drug-induced falls in older people: a review of interventions aimed at reducing the problem. Drugs Aging. 2012;29:15-30.

9. US Food and Drug Administration. Public health advisory: deaths with antipsychotics in elderly patients with behavioral disturbances. April 11, 2005. Available at:  http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm053171.htm. Accessed September 16, 2013.

10. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294:1934-1943.

11. US Food and Drug Administration. Antipsychotics, conventional and atypical. June 16, 2008. Available at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm110212.htm. Accessed September 16, 2013. 

12. Wang PS, Schneeweiss S, Avorn J, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med. 2005;353:2335-2341.

13. Ballard C, Waite J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer’s disease. Cochrane Database Syst Rev. 2006;(1):CD003476.

14. Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA. 2005;293:596-608.

15. Lonergan E, Luxenberg J, Colford JM. Haloperidol for agitation in dementia. Cochrane Database Syst Rev. 2002;(2):CD002852.

16. Schneider LS, Tariot PN, Dagerman KS, et al; CATIE-AD Study Group. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer’s disease. N Engl J Med. 2006;355:1525-1538.

17. Martinón-Torres G, Fioravanti M, Grimley EJ. Trazodone for agitation in dementia. Cochrane Database Syst Rev. 2004;(4):CD004990.

18. Birks J, Harvey RJ. Donepezil for dementia due to Alzheimer’s disease. Cochrane Database Syst Rev. 2006;(1):CD001190. 

19. McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev. 2006;(2):CD003154.

20. Raina P, Santaguida P, Ismaila A, et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med. 2008;148:379-397. 

21. Seitz DP, Adunuri N, Gill SS, et al. Antidepressants for agitation and psychosis in dementia. Cochrane Database Syst Rev. 2011;(2): CD008191.

22. Sterke CS, Ziere G, van Beeck EF, et al. Dose-response relationship between selective serotonin re-uptake inhibitors and injurious falls: a study in nursing home residents with dementia. Br J Clin Pharmacol. 2012;73:812-820.

23. Jacob S, Spinler SA. Hyponatremia associated with selective serotonin-reuptake inhibitors in older adults. Ann Pharmacother. 2006;40:1618-1622. 

24. Segal-Gidan F, Cherry D, Jones R, et al. Alzheimer’s disease management guideline: update 2008. Alzheimers Dement. 2011;7:e51-e59.

25. Rayner A, O’Brien J, Shoenbachler B. Behavior disorders of dementia: recognition and treatment. Am Fam Physician. 2006;73:647-652.

26. Ayalon L, Gum AM, Feliciano L, et al. Effectiveness of nonpharmacological interventions for the management of neuropsychiatric symptoms in patients with dementia: a systematic review. Arch Intern Med. 2006;166:2182-2188.

27. Elie M, Cole MG, Primeau FJ, et al. Delirium risk factors in elderly hospitalized patients. J Gen Intern Med. 1998;13:204-212.

28. Azermai M, Petrovic M, Elseviers MM, et al. Systematic appraisal of dementia guidelines for the management of behavioural and psychological symptoms. Aging Res Rev. 2012;11:78-86.

29. Viggo Hansen N, Jørgensen T, Ørtenblad L. Massage and touch for dementia. Cochrane Database Syst Rev. 2006;(4):CD004989.

30. Kong EH, Evans LK, Guevara JP. Nonpharmacological intervention for agitation in dementia: a systematic review and meta-analysis. Aging Ment Health. 2009;13:512-520.

31. Thorgrimsen LM, Spector A, Wiles A, et al. Aroma therapy for dementia. Cochrane Database Syst Rev. 2003;(3):CD003150.

32. Brodaty H, Arasaratnam C. Review of meta-analysis of nonpharmacological interventions for neuropsychiatric symptoms of dementia. Am J Psychiatry 2012;169:946-953.

33. Spijker A, Vernooij-Dassen M, Vasse E, et al. Effectiveness of nonpharmacological interventions in delaying the institutionalization of patients with dementia: A meta-analysis. J Am Geriatr Soc. 2008;56:1116-1128.

34. Opie J, Rosewarne R, O’Connor DW. The efficacy of psychosocial approaches to behaviour disorders in dementia: a systematic literature review. Aust N Z J Psychiatry. 1999;33:789-799.

35. Forbes D, Forbes S, Morgan DG, et al. Physical activity programs for persons with dementia. Cochrane Database Syst Rev. 2008;(3):CD006489.

36. Price JD, Hermans DG, Grimley Evans J. Subjective barriers to prevent wandering of cognitively impaired people. Cochrane Database Syst Rev. 2000;(4):CD001932.

37. Woods B, Aguirre E, Spector AE, et al. Cognitive stimulation to improve cognitive functioning in people with dementia. Cochrane Database Syst Rev. 2012;(2):CD005562.

38. Woods B, Spector A, Jones C, et al. Reminiscence therapy for dementia. Cochrane Database Syst Rev. 2005;(2):CD001120.

39. Lee H, Cameron M. Respite care for people with dementia and their carers. Cochrane Database Syst Rev. 2004;(2):CD004396.

40. Lai CK, Yeung JH, Mok V, et al. Special care units for dementia individuals with behavioural problems. Cochrane Database Syst Rev. 2009;(4):CD006470.

41. Waldemar G, Dubois B, Emre M, et al. Recommendations for the diagnosis and management of Alzheimer’s disease and other disorders associated with dementia: EFNS guideline. Eur J Neurol. 2007;14:e1-e26.

42. Oldervoll LM, Loge JH, Paltiel H, et al. The effect of a physical exercise program in palliative care: a phase II study. J Pain Symptom Manage. 2006;31:421-430.

43. Vink AC, Birks JS, Bruinsma MS, et al. Music therapy for people with dementia. Cochrane Database Syst Rev. 2004;(3):CD003477.

44. Gitlin LN, Kales HC, Lyketsos CG. Nonpharmacologic management of behavioral symptoms in dementia. JAMA. 2012;308:2020-2029.

45. Bass DM, Clark PA, Looman WJ, et al. The Cleveland Alzheimer’s managed care demonstration: outcomes after 12 months of implementation. Gerontologist. 2003;43:73-85.

46. Gitlin LN, Winter L, Dennis MP, et al.. A biobehavioral home-based intervention and the well-being of patients with dementia and their caregivers: the COPE randomized trial. JAMA. 2010;304:983-991.

47. Smith GE, Kokmen E, O’Brien PC. Risk factors for nursing home placement in a population-based dementia cohort. J Am Geriatr Soc. 2000;48:519-525.

Issue
The Journal of Family Practice - 62(10)
Issue
The Journal of Family Practice - 62(10)
Page Number
548, 550-554,557
Page Number
548, 550-554,557
Publications
Publications
Topics
Article Type
Display Headline
A nondrug approach to dementia
Display Headline
A nondrug approach to dementia
Legacy Keywords
Jaqueline Raetz; MD; dementia; antipsychotics; behavioral symptoms; nonpharmaceutical interventions; psychological symptoms; nondrug; Applied Evidence
Legacy Keywords
Jaqueline Raetz; MD; dementia; antipsychotics; behavioral symptoms; nonpharmaceutical interventions; psychological symptoms; nondrug; Applied Evidence
Sections
Article Source

PURLs Copyright

Inside the Article

Article PDF Media

When to consider Mohs surgery

Article Type
Changed
Display Headline
When to consider Mohs surgery

Practice recommendations

›    Consider recommending Mohs surgery for cancerous lesions that are long-standing or when there is a high risk of local recurrence or metastasis.  
›    Consider the procedure for the resection of tumors in cosmetically sensitive areas. 

Strength of recommendation (SOR)

A Good-quality patient-oriented evidence
B Inconsistent or limited-quality patient-oriented evidence
C Consensus, usual practice, opinion, disease-oriented evidence, case series

CASE A 64-year-old white woman with no personal or family history of skin cancer came to our practice complaining of a lesion on her right cheek (FIGURE 1) that had been present for at least 9 months. The lesion had the appearance of a “rodent bite” ulcer that the patient said bled easily when scratched and occasionally drained clear fluid. She had no other complaints. Biopsy confirmed a nodular, infiltrative basal cell carcinoma (BCC). How would you proceed?

BCC is the most common cutaneous malignancy, with an incidence of more than 1 million cases each year in the United States.1 BCCs occur more commonly in men than in women, usually on the head or neck in both sexes.2,3

Specifying BCC subtype has treatment implications. As the terminology indicates, these lesions arise from the basal cell layer of the epidermis, and they can be further defined histologically as superficial, nodular, micronodular, infiltrating, or other subtypes.

Treatment options for BCCs

Selecting a treatment modality from among the many options depends on a lesion’s subtype and its location. Comorbidity can also influence the decision, favoring nonsurgical intervention if an acute or chronic medical condition or overall health status makes a patient a poor surgical candidate.

Surgical options have the highest clearance rates with the fewest recurrences. Mohs micrographic surgery (MMS) has a cure rate of 99% for primary BCCs and 94% for recurrent lesions.4 Standard excision with appropriate margins yields cure rates of 90% and 83%, respectively.4

Superficial destructive options are typically reserved for superficial BCCs. One example, curettage with electrodessication, cures 92% of primary lesions but just 60% of recurrences.4

Additionally, noninvasive modalities such as cryosurgery, laser ablation, radiotherapy, and photodynamic therapy have varying clearance rates. Topical applications of immune system modulators and chemotherapeutic agents including imiquimod and 5-fluorouracil are also available.5 Target lesions for these modalities may include cancers located on surfaces in which surgical excision would result in unacceptable amounts of tissue loss, such as some periocular BCCs.5

CASE Given our patient’s tumor location (adjacent to the lower eyelid) and its nodular and infiltrating histologic subtype, MMS was the best treatment choice to minimize the chance of recurrence and to achieve an acceptable cosmetic outcome.

A tissue-sparing approach

MMS is a tissue-sparing cutaneous surgical technique first described by Dr. Frederick Mohs in 1941.6 The procedure uses real-time microscopic examination of all removed tissue margins, offering maximal tissue preservation and the highest cure rates of all BCC treatments.7

Compared with other surgical techniques, MMS is unique in that the surgeon also serves as the pathologist and performs reconstruction. After clearing tumor margins of all malignant tissue, the surgeon closes the wound using complex techniques such as tissue flaps and grafts that should be avoided with standard excision due to its inadequate real-time margin control.

When MMS would be the treatment of choice. While MMS may be appropriate for a number of situations, common indications include tumors that are long-standing or have a high risk of local recurrence or metastasis; affected areas where tissue preservation is important such as the face and genitalia; and patients who are immunosuppressed.7

Basics of the technique. To systematically visualize and clear 100% of tumor margins, MMS uses a cyclical process of tumor excision, pathology assessment of specimens with microscopy, and mapping of any remaining positive tissue margins noted.4 These cycles, or stages, are repeated until all excised margins are confirmed cancer free. The ability to establish this outcome with certainty is what permits Mohs surgeons to close surgical wounds with flaps, grafts, and other complex closures.

    

Advantages of MMS over excision alone. Recurrence rates of BCC after MMS are For more information on MMS, visit the American College of Mohs Surgery at www.skincancermohssurgery.org lower than those seen with excision alone. The 5-year cure rate in the treatment of primary tumors with all non-Mohs modalities combined is 91%, whereas the 5-year cure rate with Mohs surgery is 99%.8 This finding is believed to reflect the difference in the methods used to assess excised specimens histologically. In standard surgical excision, the specimen is examined using the “bread loaf” technique in which the surgical margins are examined in consecutive vertical sections (FIGURE 2).4 Because not all of the surgical margins are directly visualized with this technique, it can increase the rate of false-negative results. In contrast, specimens removed by MMS are examined in horizontal sections, and all surgical margins are directly visualized.9

 

 

Aesthetic results are another strong point of MMS. For tumor resection in cosmetically sensitive areas, MMS is the standard of care. The Mohs surgeon is trained to use closures that result in less noticeable scars and minimize distortion of surrounding tissue.

CASE With our patient, we circumscribed the clinical margins of the tumor (FIGURE 3A) before performing Mohs surgery. Two procedural stages were needed to clear all surgical margins, leaving a residual defect (FIGURE 3B). We used a cheek advancement flap to repair the wound (FIGURE 3C).
At 4 months postop, the patient was pleased with the cosmetic result (FIGURE 3D)
.

CORRESPONDENCE
Matthew Morrissey, MD, Wilford Hall Ambulatory Surgical Center, 2200 Bergquist Drive, Lackland AFB, TX 78236; matthew.morrissey@us.af.mil

References

1. Feldman S, Pearce DJ, Williford PM. Surgical decision making for basal cell carcinoma of the face. Lancet Oncol. 2008;9:1119-1120.

2. Scrivener Y, Grosshans E, Cribier B. Variations of basal cell carcinomas according to gender, age, location, and histopathological subtype. Br J Dermatol. 2002;147:41-47.

3. Harris RB, Griffith K, Moon TE. Trends in the incidence of nonmelanoma skin cancers in southeastern Arizona, 1985-1996. J Am Acad Dermatol. 2001;45:528-536.

4. Snow SN, Mikhail GR. Mohs Micrographic Surgery. 2nd ed. Madison, Wisc: University of Wisconsin Press; 2005.

5. Smith V, Walton S. Treatment of facial basal cell carcinoma: a review. J Skin Cancer. 2011;2011:380371. 

6. Mohs RE, Chemosurgery. A microscopically controlled method of cancer excision. Arch Surg. 1941;42:279-295.

7. Drake LA, Dineheart SM, Goltz RW, et al. Guidelines of care for Mohs micrographic surgery. American Academy of Dermatology. J Am Acad Dermatol. 1995;33:271-278.

8. Snow SN, Gunkel J. Mohs surgery. In: Bolongia JI, et al, eds. Dermatology. 3rd ed. Philadelphia, Pa: Saunders; 2012:2445-2457.

9. Mosterd K, Krekels GA, Nieman FH, et al. Surgical excision versus Mohs micrographic surgery for primary and recurrent basal cell carcinoma of the face: a prospective randomized controlled trial with 5 years follow up. Lancet Oncol. 2008;9:1149-1156.

Article PDF
Author and Disclosure Information

Matthew Morrissey, MD; Thomas Beachkofsky, MD; Steven Ritter, MD
Wilford Hall Ambulatory Surgical Center, Lackland AFB, Texas
matthew.morrissey@us.af.mil   

The authors reported no potential conflicts of interest relevant to this article.

Issue
The Journal of Family Practice - 62(10)
Publications
Topics
Page Number
558-559, 564
Legacy Keywords
Matthew Morrissey, MD; Thomas Beachkofsky, MD; Steven Ritter, MD; Applied Evidence; Mohs surgery; "bread loaf" technique; MMS; Mohs micrographic surgery; BCC; basal cell carcinoma
Sections
Author and Disclosure Information

Matthew Morrissey, MD; Thomas Beachkofsky, MD; Steven Ritter, MD
Wilford Hall Ambulatory Surgical Center, Lackland AFB, Texas
matthew.morrissey@us.af.mil   

The authors reported no potential conflicts of interest relevant to this article.

Author and Disclosure Information

Matthew Morrissey, MD; Thomas Beachkofsky, MD; Steven Ritter, MD
Wilford Hall Ambulatory Surgical Center, Lackland AFB, Texas
matthew.morrissey@us.af.mil   

The authors reported no potential conflicts of interest relevant to this article.

Article PDF
Article PDF

Practice recommendations

›    Consider recommending Mohs surgery for cancerous lesions that are long-standing or when there is a high risk of local recurrence or metastasis.  
›    Consider the procedure for the resection of tumors in cosmetically sensitive areas. 

Strength of recommendation (SOR)

A Good-quality patient-oriented evidence
B Inconsistent or limited-quality patient-oriented evidence
C Consensus, usual practice, opinion, disease-oriented evidence, case series

CASE A 64-year-old white woman with no personal or family history of skin cancer came to our practice complaining of a lesion on her right cheek (FIGURE 1) that had been present for at least 9 months. The lesion had the appearance of a “rodent bite” ulcer that the patient said bled easily when scratched and occasionally drained clear fluid. She had no other complaints. Biopsy confirmed a nodular, infiltrative basal cell carcinoma (BCC). How would you proceed?

BCC is the most common cutaneous malignancy, with an incidence of more than 1 million cases each year in the United States.1 BCCs occur more commonly in men than in women, usually on the head or neck in both sexes.2,3

Specifying BCC subtype has treatment implications. As the terminology indicates, these lesions arise from the basal cell layer of the epidermis, and they can be further defined histologically as superficial, nodular, micronodular, infiltrating, or other subtypes.

Treatment options for BCCs

Selecting a treatment modality from among the many options depends on a lesion’s subtype and its location. Comorbidity can also influence the decision, favoring nonsurgical intervention if an acute or chronic medical condition or overall health status makes a patient a poor surgical candidate.

Surgical options have the highest clearance rates with the fewest recurrences. Mohs micrographic surgery (MMS) has a cure rate of 99% for primary BCCs and 94% for recurrent lesions.4 Standard excision with appropriate margins yields cure rates of 90% and 83%, respectively.4

Superficial destructive options are typically reserved for superficial BCCs. One example, curettage with electrodessication, cures 92% of primary lesions but just 60% of recurrences.4

Additionally, noninvasive modalities such as cryosurgery, laser ablation, radiotherapy, and photodynamic therapy have varying clearance rates. Topical applications of immune system modulators and chemotherapeutic agents including imiquimod and 5-fluorouracil are also available.5 Target lesions for these modalities may include cancers located on surfaces in which surgical excision would result in unacceptable amounts of tissue loss, such as some periocular BCCs.5

CASE Given our patient’s tumor location (adjacent to the lower eyelid) and its nodular and infiltrating histologic subtype, MMS was the best treatment choice to minimize the chance of recurrence and to achieve an acceptable cosmetic outcome.

A tissue-sparing approach

MMS is a tissue-sparing cutaneous surgical technique first described by Dr. Frederick Mohs in 1941.6 The procedure uses real-time microscopic examination of all removed tissue margins, offering maximal tissue preservation and the highest cure rates of all BCC treatments.7

Compared with other surgical techniques, MMS is unique in that the surgeon also serves as the pathologist and performs reconstruction. After clearing tumor margins of all malignant tissue, the surgeon closes the wound using complex techniques such as tissue flaps and grafts that should be avoided with standard excision due to its inadequate real-time margin control.

When MMS would be the treatment of choice. While MMS may be appropriate for a number of situations, common indications include tumors that are long-standing or have a high risk of local recurrence or metastasis; affected areas where tissue preservation is important such as the face and genitalia; and patients who are immunosuppressed.7

Basics of the technique. To systematically visualize and clear 100% of tumor margins, MMS uses a cyclical process of tumor excision, pathology assessment of specimens with microscopy, and mapping of any remaining positive tissue margins noted.4 These cycles, or stages, are repeated until all excised margins are confirmed cancer free. The ability to establish this outcome with certainty is what permits Mohs surgeons to close surgical wounds with flaps, grafts, and other complex closures.

    

Advantages of MMS over excision alone. Recurrence rates of BCC after MMS are For more information on MMS, visit the American College of Mohs Surgery at www.skincancermohssurgery.org lower than those seen with excision alone. The 5-year cure rate in the treatment of primary tumors with all non-Mohs modalities combined is 91%, whereas the 5-year cure rate with Mohs surgery is 99%.8 This finding is believed to reflect the difference in the methods used to assess excised specimens histologically. In standard surgical excision, the specimen is examined using the “bread loaf” technique in which the surgical margins are examined in consecutive vertical sections (FIGURE 2).4 Because not all of the surgical margins are directly visualized with this technique, it can increase the rate of false-negative results. In contrast, specimens removed by MMS are examined in horizontal sections, and all surgical margins are directly visualized.9

 

 

Aesthetic results are another strong point of MMS. For tumor resection in cosmetically sensitive areas, MMS is the standard of care. The Mohs surgeon is trained to use closures that result in less noticeable scars and minimize distortion of surrounding tissue.

CASE With our patient, we circumscribed the clinical margins of the tumor (FIGURE 3A) before performing Mohs surgery. Two procedural stages were needed to clear all surgical margins, leaving a residual defect (FIGURE 3B). We used a cheek advancement flap to repair the wound (FIGURE 3C).
At 4 months postop, the patient was pleased with the cosmetic result (FIGURE 3D)
.

CORRESPONDENCE
Matthew Morrissey, MD, Wilford Hall Ambulatory Surgical Center, 2200 Bergquist Drive, Lackland AFB, TX 78236; matthew.morrissey@us.af.mil

Practice recommendations

›    Consider recommending Mohs surgery for cancerous lesions that are long-standing or when there is a high risk of local recurrence or metastasis.  
›    Consider the procedure for the resection of tumors in cosmetically sensitive areas. 

Strength of recommendation (SOR)

A Good-quality patient-oriented evidence
B Inconsistent or limited-quality patient-oriented evidence
C Consensus, usual practice, opinion, disease-oriented evidence, case series

CASE A 64-year-old white woman with no personal or family history of skin cancer came to our practice complaining of a lesion on her right cheek (FIGURE 1) that had been present for at least 9 months. The lesion had the appearance of a “rodent bite” ulcer that the patient said bled easily when scratched and occasionally drained clear fluid. She had no other complaints. Biopsy confirmed a nodular, infiltrative basal cell carcinoma (BCC). How would you proceed?

BCC is the most common cutaneous malignancy, with an incidence of more than 1 million cases each year in the United States.1 BCCs occur more commonly in men than in women, usually on the head or neck in both sexes.2,3

Specifying BCC subtype has treatment implications. As the terminology indicates, these lesions arise from the basal cell layer of the epidermis, and they can be further defined histologically as superficial, nodular, micronodular, infiltrating, or other subtypes.

Treatment options for BCCs

Selecting a treatment modality from among the many options depends on a lesion’s subtype and its location. Comorbidity can also influence the decision, favoring nonsurgical intervention if an acute or chronic medical condition or overall health status makes a patient a poor surgical candidate.

Surgical options have the highest clearance rates with the fewest recurrences. Mohs micrographic surgery (MMS) has a cure rate of 99% for primary BCCs and 94% for recurrent lesions.4 Standard excision with appropriate margins yields cure rates of 90% and 83%, respectively.4

Superficial destructive options are typically reserved for superficial BCCs. One example, curettage with electrodessication, cures 92% of primary lesions but just 60% of recurrences.4

Additionally, noninvasive modalities such as cryosurgery, laser ablation, radiotherapy, and photodynamic therapy have varying clearance rates. Topical applications of immune system modulators and chemotherapeutic agents including imiquimod and 5-fluorouracil are also available.5 Target lesions for these modalities may include cancers located on surfaces in which surgical excision would result in unacceptable amounts of tissue loss, such as some periocular BCCs.5

CASE Given our patient’s tumor location (adjacent to the lower eyelid) and its nodular and infiltrating histologic subtype, MMS was the best treatment choice to minimize the chance of recurrence and to achieve an acceptable cosmetic outcome.

A tissue-sparing approach

MMS is a tissue-sparing cutaneous surgical technique first described by Dr. Frederick Mohs in 1941.6 The procedure uses real-time microscopic examination of all removed tissue margins, offering maximal tissue preservation and the highest cure rates of all BCC treatments.7

Compared with other surgical techniques, MMS is unique in that the surgeon also serves as the pathologist and performs reconstruction. After clearing tumor margins of all malignant tissue, the surgeon closes the wound using complex techniques such as tissue flaps and grafts that should be avoided with standard excision due to its inadequate real-time margin control.

When MMS would be the treatment of choice. While MMS may be appropriate for a number of situations, common indications include tumors that are long-standing or have a high risk of local recurrence or metastasis; affected areas where tissue preservation is important such as the face and genitalia; and patients who are immunosuppressed.7

Basics of the technique. To systematically visualize and clear 100% of tumor margins, MMS uses a cyclical process of tumor excision, pathology assessment of specimens with microscopy, and mapping of any remaining positive tissue margins noted.4 These cycles, or stages, are repeated until all excised margins are confirmed cancer free. The ability to establish this outcome with certainty is what permits Mohs surgeons to close surgical wounds with flaps, grafts, and other complex closures.

    

Advantages of MMS over excision alone. Recurrence rates of BCC after MMS are For more information on MMS, visit the American College of Mohs Surgery at www.skincancermohssurgery.org lower than those seen with excision alone. The 5-year cure rate in the treatment of primary tumors with all non-Mohs modalities combined is 91%, whereas the 5-year cure rate with Mohs surgery is 99%.8 This finding is believed to reflect the difference in the methods used to assess excised specimens histologically. In standard surgical excision, the specimen is examined using the “bread loaf” technique in which the surgical margins are examined in consecutive vertical sections (FIGURE 2).4 Because not all of the surgical margins are directly visualized with this technique, it can increase the rate of false-negative results. In contrast, specimens removed by MMS are examined in horizontal sections, and all surgical margins are directly visualized.9

 

 

Aesthetic results are another strong point of MMS. For tumor resection in cosmetically sensitive areas, MMS is the standard of care. The Mohs surgeon is trained to use closures that result in less noticeable scars and minimize distortion of surrounding tissue.

CASE With our patient, we circumscribed the clinical margins of the tumor (FIGURE 3A) before performing Mohs surgery. Two procedural stages were needed to clear all surgical margins, leaving a residual defect (FIGURE 3B). We used a cheek advancement flap to repair the wound (FIGURE 3C).
At 4 months postop, the patient was pleased with the cosmetic result (FIGURE 3D)
.

CORRESPONDENCE
Matthew Morrissey, MD, Wilford Hall Ambulatory Surgical Center, 2200 Bergquist Drive, Lackland AFB, TX 78236; matthew.morrissey@us.af.mil

References

1. Feldman S, Pearce DJ, Williford PM. Surgical decision making for basal cell carcinoma of the face. Lancet Oncol. 2008;9:1119-1120.

2. Scrivener Y, Grosshans E, Cribier B. Variations of basal cell carcinomas according to gender, age, location, and histopathological subtype. Br J Dermatol. 2002;147:41-47.

3. Harris RB, Griffith K, Moon TE. Trends in the incidence of nonmelanoma skin cancers in southeastern Arizona, 1985-1996. J Am Acad Dermatol. 2001;45:528-536.

4. Snow SN, Mikhail GR. Mohs Micrographic Surgery. 2nd ed. Madison, Wisc: University of Wisconsin Press; 2005.

5. Smith V, Walton S. Treatment of facial basal cell carcinoma: a review. J Skin Cancer. 2011;2011:380371. 

6. Mohs RE, Chemosurgery. A microscopically controlled method of cancer excision. Arch Surg. 1941;42:279-295.

7. Drake LA, Dineheart SM, Goltz RW, et al. Guidelines of care for Mohs micrographic surgery. American Academy of Dermatology. J Am Acad Dermatol. 1995;33:271-278.

8. Snow SN, Gunkel J. Mohs surgery. In: Bolongia JI, et al, eds. Dermatology. 3rd ed. Philadelphia, Pa: Saunders; 2012:2445-2457.

9. Mosterd K, Krekels GA, Nieman FH, et al. Surgical excision versus Mohs micrographic surgery for primary and recurrent basal cell carcinoma of the face: a prospective randomized controlled trial with 5 years follow up. Lancet Oncol. 2008;9:1149-1156.

References

1. Feldman S, Pearce DJ, Williford PM. Surgical decision making for basal cell carcinoma of the face. Lancet Oncol. 2008;9:1119-1120.

2. Scrivener Y, Grosshans E, Cribier B. Variations of basal cell carcinomas according to gender, age, location, and histopathological subtype. Br J Dermatol. 2002;147:41-47.

3. Harris RB, Griffith K, Moon TE. Trends in the incidence of nonmelanoma skin cancers in southeastern Arizona, 1985-1996. J Am Acad Dermatol. 2001;45:528-536.

4. Snow SN, Mikhail GR. Mohs Micrographic Surgery. 2nd ed. Madison, Wisc: University of Wisconsin Press; 2005.

5. Smith V, Walton S. Treatment of facial basal cell carcinoma: a review. J Skin Cancer. 2011;2011:380371. 

6. Mohs RE, Chemosurgery. A microscopically controlled method of cancer excision. Arch Surg. 1941;42:279-295.

7. Drake LA, Dineheart SM, Goltz RW, et al. Guidelines of care for Mohs micrographic surgery. American Academy of Dermatology. J Am Acad Dermatol. 1995;33:271-278.

8. Snow SN, Gunkel J. Mohs surgery. In: Bolongia JI, et al, eds. Dermatology. 3rd ed. Philadelphia, Pa: Saunders; 2012:2445-2457.

9. Mosterd K, Krekels GA, Nieman FH, et al. Surgical excision versus Mohs micrographic surgery for primary and recurrent basal cell carcinoma of the face: a prospective randomized controlled trial with 5 years follow up. Lancet Oncol. 2008;9:1149-1156.

Issue
The Journal of Family Practice - 62(10)
Issue
The Journal of Family Practice - 62(10)
Page Number
558-559, 564
Page Number
558-559, 564
Publications
Publications
Topics
Article Type
Display Headline
When to consider Mohs surgery
Display Headline
When to consider Mohs surgery
Legacy Keywords
Matthew Morrissey, MD; Thomas Beachkofsky, MD; Steven Ritter, MD; Applied Evidence; Mohs surgery; "bread loaf" technique; MMS; Mohs micrographic surgery; BCC; basal cell carcinoma
Legacy Keywords
Matthew Morrissey, MD; Thomas Beachkofsky, MD; Steven Ritter, MD; Applied Evidence; Mohs surgery; "bread loaf" technique; MMS; Mohs micrographic surgery; BCC; basal cell carcinoma
Sections
Article Source

PURLs Copyright

Inside the Article

Article PDF Media

Peripheral neuropathy linked to obstructive sleep apnea?

Article Type
Changed
Display Headline
Peripheral neuropathy linked to obstructive sleep apnea?

CASE A 57-year-old white woman presented with symptoms of bilateral “stocking-like numbness” and the sensation of “wearing socks for a few weeks” but denied any injury, previous chemotherapy, or diabetes. Her medical history was positive for untreated obstructive sleep apnea (OSA), obesity (body mass index, 36 kg/m2), osteoarthritis in various joints, impaired fasting glucose with normal glycosylated hemoglobin (HbA1c), hypertension, gastroesophageal reflux disease, hypothyroidism, hypercholesterolemia, and osteoporosis.

Our initial examination revealed decreased sensation to light palpation and pin prick over the distal portion of her lower extremities in a stocking-like fashion. Proprioception was decreased at the distal joint of the big toe. Her deep tendon reflex pattern was symmetric with 2+ at the knees, ankles, and toes. The rest of her lower extremity exam was within normal limits and there were no obvious vascular abnormalities.

Given the suspicion of peripheral neuropathy, the patient underwent laboratory tests and a nerve conduction study. Vitamin B12, vitamin B1, methylmalonic acid (MMA), thyroid function, thyroid peroxidase (TPO), serum protein electrophoresis (SPEP), rapid plasma reagin (RPR), sedimentation rate, vitamin D, complete blood count, and chemistry profile 24 were all negative. The antinuclear antibody test revealed a homogenous 1:80 titer with a negative nuclear deoxyribonucleic acid. Her fasting glucose had been elevated between 107 to 117 mg/dL in the last 5 years but HbA1c was normal (5.8%). The patient had not been diagnosed with diabetes and her latest glucose values had been stable.

However, electromyography and a nerve conduction study were abnormal, with electrophysiological evidence of mild axonal polyneuropathy. During the month prior to her presentation, she had developed burning pain in addition to the numbness/stocking sensation. Pregabalin, gabapentin, duloxetine, celecoxib, hydrocodone, methadone, and other medications were ineffective. Eventually the foot pain became so severe—she described it as “walking on tacks”—that she was unable to walk.

Our team decided to do a nerve block to relieve the pain. Initially she underwent right and later left peroneal and posterior tibial nerve blocks, which gave her immediate relief that lasted about 2 months.

Relief from the pain, but what about the OSA symptoms?

In the meantime, our patient developed increasing OSA symptoms, including snoring, nonrestorative sleep, daytime somnolence, and fatigue. (To learn more about OSA, see “Obstructive sleep apnea: A diagnostic and treatment guide” on page 565.)

Her history of mild-to-moderate OSA dated back 2 years, and included an apnea-hypopnea index (AHI) of 20 events per hour and 133 episodes of oxygen desaturation with a low O2 desaturation of 83%. The patient had never been treated, however, because she felt that she couldn’t tolerate the continuous positive airway pressure (CPAP) mask.

The patient finally agreed to a CPAP titration study. Her AHI improved from 20 to <2 events per hour; the oxygen desaturation dropped from 133 to 104 episodes; and the lowest O2 desaturation went from 83% to 85%.

When we initially started CPAP, our patient did not tolerate it very well. However, after consulting with our sleep clinic, she was placed on bilevel positive airway pressure, which she did tolerate. Surprisingly, she also noticed immediate improvement of the neuropathic foot pain; after a few weeks it resolved completely.

Still no foot pain…We continue to follow the patient’s progress and, after 3 years, she remains free of foot pain. Her initial numbness remains, however. She has not After starting CPAP, the patient noticed immediate improvement of the neuropathic foot pain; after a few weeks, it resolved completely. developed diabetes, with similar fasting sugar levels and an HbA1c of 5.4%. She is not taking any medication for neuropathic pain, but remains on methadone for unrelated severe intractable osteoarthritic pain of the lumbar spine, bilateral knee joints, and left hip.

The link between sleep apnea and neuropathy

Our case report suggests that clinicians should consider OSA as a cause of neuropathic pain. A recent review of the literature supports the relationship between the 2 conditions.

The prevalence of neuropathy in the general population is 2.4%, rising to 8% with advancing age.1 Many different types of peripheral neuropathy have been described; they have different symptoms and characteristics, depending on the specific part of the nervous system that is affected.2

The literature reveals a strong association between OSA and peripheral neuropathy and sight-threatening retinopathy.3 One study found that nearly 60% of patients with diabetes and OSA also have peripheral neuropathy.4 Another report found that OSA is an independent risk factor for axonal damage of peripheral nerves.5 Furthermore, a case-control study revealed that the impaired neural function is at least partly reversible with treatment for sleep apnea.4 Finally, Tahrani et al6 have found that “neuropathy prevalence was higher in patients with OSA than those without” (60% vs 27%; P<.001), which supports our case finding.

 

 

The specific mechanism linking OSA and neuropathy remains elusive, but the evidence suggests that peripheral nervous tissue is affected by chronic endoneural hypoxia in this patient population.7 In patients with OSA, 2 types of nerve dysfunction are apparent: ischemia-related axonal degeneration and resistance to ischemic nerve failure.8

An approach worth considering. While nerve blocks did provide some relief for our patient, they are not a long-term solution. To our knowledge, this case report is the first one published in the United States describing resolution of neuropathic pain by treatment of OSA. This approach is certainly worth considering in patients who have not responded to more traditional therapy.

Correspondence
Fong Wong, DDS, MS, Associate Professor, Department of Restorative Dental Sciences, College of Dentistry, University of Florida, 1395 Center Drive, PO Box 100435, Gainesville, FL 32610; Fwong@dental.ufl.edu

References

 

1. Martyn C, Hughes R. Epidemiology of peripheral neuropathy. J Neurol Neurosurg Psychiatry. 1997;62:310-318.

2. NINDS peripheral neuropathy information page. Available at: http://www.ninds.nih.gov/disorders/peripheralneuropathy/peripheralneuropathy.htm. Last updated September 19, 2012. Accessed September 16, 2013.

3. Waller E, Bendel R, Kaplan J. Sleep disorders and the eye. Mayo Clin Proc. 2008;83:1251-1261.

4. Dziewas R, Schilling M, Engel P, et al. Treatment for obstructive sleep apnoea: effect on peripheral nerve function. J Neurol Neurosurg Psychiatry. 2007;78:295-297.

5. Ludemann P, Dziewas R, Soros P, et al. Axonal polyneuropathy in obstructive sleep apnoea. J Neurol Neurosurg Psychiatry. 2001;70:685-687.

6. Tahrani AA, Ali A, Raymond NT, et al. Obstructive sleep apnea and diabetic neuropathy: a novel association in patients with type 2 diabetes. Am J Respir Crit Care Med. 2012;186:434-441.

7. Pfeiffer G, Kunze K, Bruch M, et al. Polyneuropathy associated with chronic hypoxaemia: prevalence in patients with chronic obstructive pulmonary disease. J Neurol. 1990;237:230-233.

8. Mayer P, Dematteis M, Pepin J, et al. Peripheral neuropathy in sleep apnea. A tissue marker of the severity of nocturnal desaturation. Am J Respir Crit Care Med. 1999;159:213-219.

Article PDF
Author and Disclosure Information

 

Siegfried Schmidt, MD, PhD; Anthony Rodrigues, MD; Maria Elisa Lupi, MD; Fong Wong, DDS, MS
Department of Community Health and Family Medicine, College of Medicine (Drs. Schmidt and Lupi), Department of Restorative Dental Sciences, College of Dentistry (Dr. Wong), University of Florida, Gainesville; Department of Child Neurology, Floating Hospital for Children at Tufts Medical Center and Tufts University School of Medicine, Boston, Mass (Dr. Rodrigues)
Fwong@dental.ufl.edu

The authors reported no potential conflict of interest relevant to this article.

Issue
The Journal of Family Practice - 62(10)
Publications
Topics
Page Number
577-578
Legacy Keywords
Siegfried Schmidt; MD; PhD; Anthony Rodrigues; MD; Maria Elisa Lupi; MD; Fong Wong; DDS; MS; Applied Evidence; obstructive sleep apnea; OSA; peripheral neuropathy
Sections
Author and Disclosure Information

 

Siegfried Schmidt, MD, PhD; Anthony Rodrigues, MD; Maria Elisa Lupi, MD; Fong Wong, DDS, MS
Department of Community Health and Family Medicine, College of Medicine (Drs. Schmidt and Lupi), Department of Restorative Dental Sciences, College of Dentistry (Dr. Wong), University of Florida, Gainesville; Department of Child Neurology, Floating Hospital for Children at Tufts Medical Center and Tufts University School of Medicine, Boston, Mass (Dr. Rodrigues)
Fwong@dental.ufl.edu

The authors reported no potential conflict of interest relevant to this article.

Author and Disclosure Information

 

Siegfried Schmidt, MD, PhD; Anthony Rodrigues, MD; Maria Elisa Lupi, MD; Fong Wong, DDS, MS
Department of Community Health and Family Medicine, College of Medicine (Drs. Schmidt and Lupi), Department of Restorative Dental Sciences, College of Dentistry (Dr. Wong), University of Florida, Gainesville; Department of Child Neurology, Floating Hospital for Children at Tufts Medical Center and Tufts University School of Medicine, Boston, Mass (Dr. Rodrigues)
Fwong@dental.ufl.edu

The authors reported no potential conflict of interest relevant to this article.

Article PDF
Article PDF

CASE A 57-year-old white woman presented with symptoms of bilateral “stocking-like numbness” and the sensation of “wearing socks for a few weeks” but denied any injury, previous chemotherapy, or diabetes. Her medical history was positive for untreated obstructive sleep apnea (OSA), obesity (body mass index, 36 kg/m2), osteoarthritis in various joints, impaired fasting glucose with normal glycosylated hemoglobin (HbA1c), hypertension, gastroesophageal reflux disease, hypothyroidism, hypercholesterolemia, and osteoporosis.

Our initial examination revealed decreased sensation to light palpation and pin prick over the distal portion of her lower extremities in a stocking-like fashion. Proprioception was decreased at the distal joint of the big toe. Her deep tendon reflex pattern was symmetric with 2+ at the knees, ankles, and toes. The rest of her lower extremity exam was within normal limits and there were no obvious vascular abnormalities.

Given the suspicion of peripheral neuropathy, the patient underwent laboratory tests and a nerve conduction study. Vitamin B12, vitamin B1, methylmalonic acid (MMA), thyroid function, thyroid peroxidase (TPO), serum protein electrophoresis (SPEP), rapid plasma reagin (RPR), sedimentation rate, vitamin D, complete blood count, and chemistry profile 24 were all negative. The antinuclear antibody test revealed a homogenous 1:80 titer with a negative nuclear deoxyribonucleic acid. Her fasting glucose had been elevated between 107 to 117 mg/dL in the last 5 years but HbA1c was normal (5.8%). The patient had not been diagnosed with diabetes and her latest glucose values had been stable.

However, electromyography and a nerve conduction study were abnormal, with electrophysiological evidence of mild axonal polyneuropathy. During the month prior to her presentation, she had developed burning pain in addition to the numbness/stocking sensation. Pregabalin, gabapentin, duloxetine, celecoxib, hydrocodone, methadone, and other medications were ineffective. Eventually the foot pain became so severe—she described it as “walking on tacks”—that she was unable to walk.

Our team decided to do a nerve block to relieve the pain. Initially she underwent right and later left peroneal and posterior tibial nerve blocks, which gave her immediate relief that lasted about 2 months.

Relief from the pain, but what about the OSA symptoms?

In the meantime, our patient developed increasing OSA symptoms, including snoring, nonrestorative sleep, daytime somnolence, and fatigue. (To learn more about OSA, see “Obstructive sleep apnea: A diagnostic and treatment guide” on page 565.)

Her history of mild-to-moderate OSA dated back 2 years, and included an apnea-hypopnea index (AHI) of 20 events per hour and 133 episodes of oxygen desaturation with a low O2 desaturation of 83%. The patient had never been treated, however, because she felt that she couldn’t tolerate the continuous positive airway pressure (CPAP) mask.

The patient finally agreed to a CPAP titration study. Her AHI improved from 20 to <2 events per hour; the oxygen desaturation dropped from 133 to 104 episodes; and the lowest O2 desaturation went from 83% to 85%.

When we initially started CPAP, our patient did not tolerate it very well. However, after consulting with our sleep clinic, she was placed on bilevel positive airway pressure, which she did tolerate. Surprisingly, she also noticed immediate improvement of the neuropathic foot pain; after a few weeks it resolved completely.

Still no foot pain…We continue to follow the patient’s progress and, after 3 years, she remains free of foot pain. Her initial numbness remains, however. She has not After starting CPAP, the patient noticed immediate improvement of the neuropathic foot pain; after a few weeks, it resolved completely. developed diabetes, with similar fasting sugar levels and an HbA1c of 5.4%. She is not taking any medication for neuropathic pain, but remains on methadone for unrelated severe intractable osteoarthritic pain of the lumbar spine, bilateral knee joints, and left hip.

The link between sleep apnea and neuropathy

Our case report suggests that clinicians should consider OSA as a cause of neuropathic pain. A recent review of the literature supports the relationship between the 2 conditions.

The prevalence of neuropathy in the general population is 2.4%, rising to 8% with advancing age.1 Many different types of peripheral neuropathy have been described; they have different symptoms and characteristics, depending on the specific part of the nervous system that is affected.2

The literature reveals a strong association between OSA and peripheral neuropathy and sight-threatening retinopathy.3 One study found that nearly 60% of patients with diabetes and OSA also have peripheral neuropathy.4 Another report found that OSA is an independent risk factor for axonal damage of peripheral nerves.5 Furthermore, a case-control study revealed that the impaired neural function is at least partly reversible with treatment for sleep apnea.4 Finally, Tahrani et al6 have found that “neuropathy prevalence was higher in patients with OSA than those without” (60% vs 27%; P<.001), which supports our case finding.

 

 

The specific mechanism linking OSA and neuropathy remains elusive, but the evidence suggests that peripheral nervous tissue is affected by chronic endoneural hypoxia in this patient population.7 In patients with OSA, 2 types of nerve dysfunction are apparent: ischemia-related axonal degeneration and resistance to ischemic nerve failure.8

An approach worth considering. While nerve blocks did provide some relief for our patient, they are not a long-term solution. To our knowledge, this case report is the first one published in the United States describing resolution of neuropathic pain by treatment of OSA. This approach is certainly worth considering in patients who have not responded to more traditional therapy.

Correspondence
Fong Wong, DDS, MS, Associate Professor, Department of Restorative Dental Sciences, College of Dentistry, University of Florida, 1395 Center Drive, PO Box 100435, Gainesville, FL 32610; Fwong@dental.ufl.edu

CASE A 57-year-old white woman presented with symptoms of bilateral “stocking-like numbness” and the sensation of “wearing socks for a few weeks” but denied any injury, previous chemotherapy, or diabetes. Her medical history was positive for untreated obstructive sleep apnea (OSA), obesity (body mass index, 36 kg/m2), osteoarthritis in various joints, impaired fasting glucose with normal glycosylated hemoglobin (HbA1c), hypertension, gastroesophageal reflux disease, hypothyroidism, hypercholesterolemia, and osteoporosis.

Our initial examination revealed decreased sensation to light palpation and pin prick over the distal portion of her lower extremities in a stocking-like fashion. Proprioception was decreased at the distal joint of the big toe. Her deep tendon reflex pattern was symmetric with 2+ at the knees, ankles, and toes. The rest of her lower extremity exam was within normal limits and there were no obvious vascular abnormalities.

Given the suspicion of peripheral neuropathy, the patient underwent laboratory tests and a nerve conduction study. Vitamin B12, vitamin B1, methylmalonic acid (MMA), thyroid function, thyroid peroxidase (TPO), serum protein electrophoresis (SPEP), rapid plasma reagin (RPR), sedimentation rate, vitamin D, complete blood count, and chemistry profile 24 were all negative. The antinuclear antibody test revealed a homogenous 1:80 titer with a negative nuclear deoxyribonucleic acid. Her fasting glucose had been elevated between 107 to 117 mg/dL in the last 5 years but HbA1c was normal (5.8%). The patient had not been diagnosed with diabetes and her latest glucose values had been stable.

However, electromyography and a nerve conduction study were abnormal, with electrophysiological evidence of mild axonal polyneuropathy. During the month prior to her presentation, she had developed burning pain in addition to the numbness/stocking sensation. Pregabalin, gabapentin, duloxetine, celecoxib, hydrocodone, methadone, and other medications were ineffective. Eventually the foot pain became so severe—she described it as “walking on tacks”—that she was unable to walk.

Our team decided to do a nerve block to relieve the pain. Initially she underwent right and later left peroneal and posterior tibial nerve blocks, which gave her immediate relief that lasted about 2 months.

Relief from the pain, but what about the OSA symptoms?

In the meantime, our patient developed increasing OSA symptoms, including snoring, nonrestorative sleep, daytime somnolence, and fatigue. (To learn more about OSA, see “Obstructive sleep apnea: A diagnostic and treatment guide” on page 565.)

Her history of mild-to-moderate OSA dated back 2 years, and included an apnea-hypopnea index (AHI) of 20 events per hour and 133 episodes of oxygen desaturation with a low O2 desaturation of 83%. The patient had never been treated, however, because she felt that she couldn’t tolerate the continuous positive airway pressure (CPAP) mask.

The patient finally agreed to a CPAP titration study. Her AHI improved from 20 to <2 events per hour; the oxygen desaturation dropped from 133 to 104 episodes; and the lowest O2 desaturation went from 83% to 85%.

When we initially started CPAP, our patient did not tolerate it very well. However, after consulting with our sleep clinic, she was placed on bilevel positive airway pressure, which she did tolerate. Surprisingly, she also noticed immediate improvement of the neuropathic foot pain; after a few weeks it resolved completely.

Still no foot pain…We continue to follow the patient’s progress and, after 3 years, she remains free of foot pain. Her initial numbness remains, however. She has not After starting CPAP, the patient noticed immediate improvement of the neuropathic foot pain; after a few weeks, it resolved completely. developed diabetes, with similar fasting sugar levels and an HbA1c of 5.4%. She is not taking any medication for neuropathic pain, but remains on methadone for unrelated severe intractable osteoarthritic pain of the lumbar spine, bilateral knee joints, and left hip.

The link between sleep apnea and neuropathy

Our case report suggests that clinicians should consider OSA as a cause of neuropathic pain. A recent review of the literature supports the relationship between the 2 conditions.

The prevalence of neuropathy in the general population is 2.4%, rising to 8% with advancing age.1 Many different types of peripheral neuropathy have been described; they have different symptoms and characteristics, depending on the specific part of the nervous system that is affected.2

The literature reveals a strong association between OSA and peripheral neuropathy and sight-threatening retinopathy.3 One study found that nearly 60% of patients with diabetes and OSA also have peripheral neuropathy.4 Another report found that OSA is an independent risk factor for axonal damage of peripheral nerves.5 Furthermore, a case-control study revealed that the impaired neural function is at least partly reversible with treatment for sleep apnea.4 Finally, Tahrani et al6 have found that “neuropathy prevalence was higher in patients with OSA than those without” (60% vs 27%; P<.001), which supports our case finding.

 

 

The specific mechanism linking OSA and neuropathy remains elusive, but the evidence suggests that peripheral nervous tissue is affected by chronic endoneural hypoxia in this patient population.7 In patients with OSA, 2 types of nerve dysfunction are apparent: ischemia-related axonal degeneration and resistance to ischemic nerve failure.8

An approach worth considering. While nerve blocks did provide some relief for our patient, they are not a long-term solution. To our knowledge, this case report is the first one published in the United States describing resolution of neuropathic pain by treatment of OSA. This approach is certainly worth considering in patients who have not responded to more traditional therapy.

Correspondence
Fong Wong, DDS, MS, Associate Professor, Department of Restorative Dental Sciences, College of Dentistry, University of Florida, 1395 Center Drive, PO Box 100435, Gainesville, FL 32610; Fwong@dental.ufl.edu

References

 

1. Martyn C, Hughes R. Epidemiology of peripheral neuropathy. J Neurol Neurosurg Psychiatry. 1997;62:310-318.

2. NINDS peripheral neuropathy information page. Available at: http://www.ninds.nih.gov/disorders/peripheralneuropathy/peripheralneuropathy.htm. Last updated September 19, 2012. Accessed September 16, 2013.

3. Waller E, Bendel R, Kaplan J. Sleep disorders and the eye. Mayo Clin Proc. 2008;83:1251-1261.

4. Dziewas R, Schilling M, Engel P, et al. Treatment for obstructive sleep apnoea: effect on peripheral nerve function. J Neurol Neurosurg Psychiatry. 2007;78:295-297.

5. Ludemann P, Dziewas R, Soros P, et al. Axonal polyneuropathy in obstructive sleep apnoea. J Neurol Neurosurg Psychiatry. 2001;70:685-687.

6. Tahrani AA, Ali A, Raymond NT, et al. Obstructive sleep apnea and diabetic neuropathy: a novel association in patients with type 2 diabetes. Am J Respir Crit Care Med. 2012;186:434-441.

7. Pfeiffer G, Kunze K, Bruch M, et al. Polyneuropathy associated with chronic hypoxaemia: prevalence in patients with chronic obstructive pulmonary disease. J Neurol. 1990;237:230-233.

8. Mayer P, Dematteis M, Pepin J, et al. Peripheral neuropathy in sleep apnea. A tissue marker of the severity of nocturnal desaturation. Am J Respir Crit Care Med. 1999;159:213-219.

References

 

1. Martyn C, Hughes R. Epidemiology of peripheral neuropathy. J Neurol Neurosurg Psychiatry. 1997;62:310-318.

2. NINDS peripheral neuropathy information page. Available at: http://www.ninds.nih.gov/disorders/peripheralneuropathy/peripheralneuropathy.htm. Last updated September 19, 2012. Accessed September 16, 2013.

3. Waller E, Bendel R, Kaplan J. Sleep disorders and the eye. Mayo Clin Proc. 2008;83:1251-1261.

4. Dziewas R, Schilling M, Engel P, et al. Treatment for obstructive sleep apnoea: effect on peripheral nerve function. J Neurol Neurosurg Psychiatry. 2007;78:295-297.

5. Ludemann P, Dziewas R, Soros P, et al. Axonal polyneuropathy in obstructive sleep apnoea. J Neurol Neurosurg Psychiatry. 2001;70:685-687.

6. Tahrani AA, Ali A, Raymond NT, et al. Obstructive sleep apnea and diabetic neuropathy: a novel association in patients with type 2 diabetes. Am J Respir Crit Care Med. 2012;186:434-441.

7. Pfeiffer G, Kunze K, Bruch M, et al. Polyneuropathy associated with chronic hypoxaemia: prevalence in patients with chronic obstructive pulmonary disease. J Neurol. 1990;237:230-233.

8. Mayer P, Dematteis M, Pepin J, et al. Peripheral neuropathy in sleep apnea. A tissue marker of the severity of nocturnal desaturation. Am J Respir Crit Care Med. 1999;159:213-219.

Issue
The Journal of Family Practice - 62(10)
Issue
The Journal of Family Practice - 62(10)
Page Number
577-578
Page Number
577-578
Publications
Publications
Topics
Article Type
Display Headline
Peripheral neuropathy linked to obstructive sleep apnea?
Display Headline
Peripheral neuropathy linked to obstructive sleep apnea?
Legacy Keywords
Siegfried Schmidt; MD; PhD; Anthony Rodrigues; MD; Maria Elisa Lupi; MD; Fong Wong; DDS; MS; Applied Evidence; obstructive sleep apnea; OSA; peripheral neuropathy
Legacy Keywords
Siegfried Schmidt; MD; PhD; Anthony Rodrigues; MD; Maria Elisa Lupi; MD; Fong Wong; DDS; MS; Applied Evidence; obstructive sleep apnea; OSA; peripheral neuropathy
Sections
Disallow All Ads
Alternative CME
Article PDF Media

Sweet Syndrome: The Uncommon Painful Rash

Article Type
Changed
Display Headline
Sweet Syndrome: The Uncommon Painful Rash

Article PDF
Author and Disclosure Information

LT Mohenish Singh, DO, MS, MC, USN; CDR Mark Eaton, MD; and LCDR Robert Staten, MD

Issue
Federal Practitioner - 30(9)
Publications
Topics
Page Number
19-20
Legacy Keywords
Sweet syndrome, neutrophilic dermatosis, rash, acute febrile neutrophilic dermatosis, LT Mohenish Singh, CDR Mark Eaton, LCDR Robert Staten
Sections
Author and Disclosure Information

LT Mohenish Singh, DO, MS, MC, USN; CDR Mark Eaton, MD; and LCDR Robert Staten, MD

Author and Disclosure Information

LT Mohenish Singh, DO, MS, MC, USN; CDR Mark Eaton, MD; and LCDR Robert Staten, MD

Article PDF
Article PDF

Issue
Federal Practitioner - 30(9)
Issue
Federal Practitioner - 30(9)
Page Number
19-20
Page Number
19-20
Publications
Publications
Topics
Article Type
Display Headline
Sweet Syndrome: The Uncommon Painful Rash
Display Headline
Sweet Syndrome: The Uncommon Painful Rash
Legacy Keywords
Sweet syndrome, neutrophilic dermatosis, rash, acute febrile neutrophilic dermatosis, LT Mohenish Singh, CDR Mark Eaton, LCDR Robert Staten
Legacy Keywords
Sweet syndrome, neutrophilic dermatosis, rash, acute febrile neutrophilic dermatosis, LT Mohenish Singh, CDR Mark Eaton, LCDR Robert Staten
Sections
Article Source

PURLs Copyright

Inside the Article

Article PDF Media

Traumatic Obterator Hip Traumatic Obterator Hip Dislocation in a 9-Year-Old Boy Dislocation in a 9-Year-Old Boy

Article Type
Changed
Display Headline
Traumatic Obterator Hip Traumatic Obterator Hip Dislocation in a 9-Year-Old Boy Dislocation in a 9-Year-Old Boy

Author and Disclosure Information

Issue
The American Journal of Orthopedics - 42(9)
Publications
Topics
Page Number
E81-E83
Legacy Keywords
ajo, the american journal of orthopedics, hip, dislocation, pediatrics
Sections
Author and Disclosure Information

Author and Disclosure Information

Issue
The American Journal of Orthopedics - 42(9)
Issue
The American Journal of Orthopedics - 42(9)
Page Number
E81-E83
Page Number
E81-E83
Publications
Publications
Topics
Article Type
Display Headline
Traumatic Obterator Hip Traumatic Obterator Hip Dislocation in a 9-Year-Old Boy Dislocation in a 9-Year-Old Boy
Display Headline
Traumatic Obterator Hip Traumatic Obterator Hip Dislocation in a 9-Year-Old Boy Dislocation in a 9-Year-Old Boy
Legacy Keywords
ajo, the american journal of orthopedics, hip, dislocation, pediatrics
Legacy Keywords
ajo, the american journal of orthopedics, hip, dislocation, pediatrics
Sections
Article Source

PURLs Copyright

Inside the Article